subject:(bone metastases)

University of Toronto

1. Burke, Mikhail Viktor. Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases.

Degree: PhD, 2018, University of Toronto

► Approximately 1/3 of all cancer patients suffer from spinal metastases. These metastases impact the equilibrium of the bone remodeling process, exhibiting excess bone-formation (osteoblastic), excess… (more)

▼ Approximately 1/3 of all cancer patients suffer from spinal metastases. These metastases impact the equilibrium of the bone remodeling process, exhibiting excess bone-formation (osteoblastic), excess bone-resorption (osteolytic) or a mixture of the two. Previous work has assessed the impact of metastatic involvement on bone microarchitecture and mineral content, establishing relationships between these characteristics and mechanical behaviour. However, less well characterized are the effects of metastatic growth on the intrinsic features of the composite that is bone tissue. In combination with previously established methodologies to characterize the microarchitecture and mineral content of metastatic vertebrae, this work sought to utilize multiple imaging and analytical techniques to characterize the hydroxyapatite and collagen constituents of healthy and metastatic vertebral bone tissue from established athymic rat models of osteolytic and mixed vertebral metastases. Whole-bone measured changes were observed in collagen cross-linking and mineral crystal dimensions, within osteolytic vertebrae compared to healthy controls. Locally measured collagen organization and mineralization of bone tissue were found to be modified with metastatic involvement; with pathological osteoblastic new bone growth demonstrating stark differences compared to healthy controls. Tissue-level collagen features, assessed both globally (collagen cross-linking, proline concentration) and locally measured (collagen organization), were correlated to whole vertebral mechanical behaviour and the material level behaviour of bone tissue respectively. These changes in collagen cross-linking and organization, secondary to metastasis, were shown to significantly impact both tissue-level and whole vertebral mechanical behaviour independent of mineral content and bone microarchitecture. This work has created a robust characterization of the impact of metastasis on vertebral bone quality. As such, it provides a foundation from which it is possible to study the effects of treatments on metastatically-involved vertebral bone, which may ultimately improve the prediction of failure and direct treatment optimized to individual patients with spinal metastases. Advisors/Committee Members: Whyne, Cari, Yee, Albert, Biomedical Engineering.

Subjects/Keywords: Bone Quality; Metastases; Vertebra; 0541

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Burke, M. V. (2018). Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases. (Doctoral Dissertation). University of Toronto. Retrieved from http://hdl.handle.net/1807/82967

Chicago Manual of Style (16^th Edition):

Burke, Mikhail Viktor. “Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases.” 2018. Doctoral Dissertation, University of Toronto. Accessed March 08, 2021. http://hdl.handle.net/1807/82967.

MLA Handbook (7^th Edition):

Burke, Mikhail Viktor. “Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases.” 2018. Web. 08 Mar 2021.

Vancouver:

Burke MV. Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases. [Internet] [Doctoral dissertation]. University of Toronto; 2018. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/1807/82967.

Council of Science Editors:

Burke MV. Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases. [Doctoral Dissertation]. University of Toronto; 2018. Available from: http://hdl.handle.net/1807/82967

2. Hagberg Thulin, Malin. The regulatory role of osteoblasts in castration-resistant growth of prostate cancer.

Degree: 2015, University of Gothenburg / Göteborgs Universitet

URL: http://hdl.handle.net/2077/38761

► Bone metastasis of a predominantly osteoblastic (sclerotic) nature is the outcome for the vast majority of patients with castration-resistant prostate cancer (CRPC). Pathologically, osteoblastic tumors… (more)

▼ Bone metastasis of a predominantly osteoblastic (sclerotic) nature is the outcome for the vast majority of patients with castration-resistant prostate cancer (CRPC). Pathologically, osteoblastic tumors are characterized by excessive bone formation resulting in decreased quality of life due to severe pain, fractures, nerve compression, and a suppressed immune system. Despite the success of novel therapeutic approaches, castration-resistant tumors remain the primary unsolved obstacle for patient survival. Therefore, an improved understanding of the molecular mechanisms behind the osteoblastic growth of CRPC is important in the search for novel therapeutic strategies. The aim of this thesis was to investigate the specific role of osteoblasts in the growth of prostate cancer in bone. By establishing and characterizing a novel model of sclerotic CRPC, it was demonstrated that both osteoblasts and prostate cancer cells are potential mediators of bone formation. It was further demonstrated that osteoblasts promote the osteogenic and metastatic progression of CRPC cells and potentiate the cross talk between CRPC and bone cells. Moreover, it was shown that osteoblasts induce and alter steroidogenesis in the CRPC cells by increasing the expression of steroidogenic enzymes in a similar manner to what has previously been described in bone metastases from patients. Further studies reveled that Runt-related transcription factor 2 (Runx2) – which is under the control of osteoblasts – is a putative regulator of de novo steroid synthesis in osteogenic CRPC cells, and this mimics a mechanism of steroid synthesis previously only described in osteoblasts. Finally, a preclinical study with tasquinimod showed that this drug efficiently impaired the establishment of bone metastases in mice by interfering with the osteoblastic pre-metastatic niche and osteoblastic activity, thus emphasizing the role of osteoblasts in the early phases of the metastatic process. In summary, the studies performed in this thesis have characterized the role of osteoblasts in castration-resistant growth of prostate cancer in bone and suggest that osteoblasts could be an attractive target for the development of novel therapeutic approaches. A better understanding of the osteoblast–tumor cell interaction might facilitate the design of treatment strategies targeting the osteoblasts as a way to inhibit the metastatic process and thus bypass the castration resistance of CRPC bone metastases.

Subjects/Keywords: castration-resistant prostate cancer; bone metastases; osteoblasts

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Hagberg Thulin, M. (2015). The regulatory role of osteoblasts in castration-resistant growth of prostate cancer. (Thesis). University of Gothenburg / Göteborgs Universitet. Retrieved from http://hdl.handle.net/2077/38761

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Hagberg Thulin, Malin. “The regulatory role of osteoblasts in castration-resistant growth of prostate cancer.” 2015. Thesis, University of Gothenburg / Göteborgs Universitet. Accessed March 08, 2021. http://hdl.handle.net/2077/38761.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Hagberg Thulin, Malin. “The regulatory role of osteoblasts in castration-resistant growth of prostate cancer.” 2015. Web. 08 Mar 2021.

Vancouver:

Hagberg Thulin M. The regulatory role of osteoblasts in castration-resistant growth of prostate cancer. [Internet] [Thesis]. University of Gothenburg / Göteborgs Universitet; 2015. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/2077/38761.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Hagberg Thulin M. The regulatory role of osteoblasts in castration-resistant growth of prostate cancer. [Thesis]. University of Gothenburg / Göteborgs Universitet; 2015. Available from: http://hdl.handle.net/2077/38761

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Rice University

3. Sablatura, Lindsey Kay. Complex 3D Culture Models for the Study of Bone Metastatic Prostate Cancer.

Degree: PhD, Natural Sciences, 2020, Rice University

URL: http://hdl.handle.net/1911/108397

► Prostate cancer (PCa) is the most prevalent form of cancer in men. Despite the enormous resource expenditures on research and development, few advances have been… (more)

▼ Prostate cancer (PCa) is the most prevalent form of cancer in men. Despite the enormous resource expenditures on research and development, few advances have been made that improve therapeutic outcomes for patients with relapsed or bone metastatic disease. The high attrition rate of potential anti-cancer drugs entering clinical trials indicates the need for a shift in our approach to modeling metastatic tumors in preclinical studies. As evidence mounts of the importance of microenvironmental cues in tumorigenesis, metastasis, treatment response, and recurrence, research has sought to bridge the gap between in vivo biological relevance and in vitro accessibility and throughput. Three-dimensional (3D) culture models allow experimental control over variables not easily manipulatable in vivo using mouse models, including the cell types and extracellular matrix cues present in the tumor microenvironment (TME). These high content models also support real time imaging of cancer cell behavior as they contact with other cells in the TME. Perfusable models can be used further, not only to add and remove nutrients and waste from cultured cells, but also to introduce perturbagens including anti-cancer drugs for testing personalized oncology. With this goal in mind, these studies tested the hypothesis that the use of complex 3D models containing cancer, stroma, and endothelial cells to reconstitute cellular interactions can replicate events that occur in the bone metastatic niche, allowing investigation into new methods of disrupting growth and progression of bone metastatic disease. Work described in chapters 2 and 3 developed a new high-content, perfusable, hydrogel-based system that permitted the tri-culture of diverse PCa patient-derived xenograft cells with microvascular endothelial cells and tumor stromal cells. The applications of this new pre-clinical model for drug screening and the study of cancer biology were demonstrated. Work in chapter 4 constructed a model of the bone marrow TME to examine endothelial cell promotion of PCa death/dormancy in the bone metastatic niche. Together, the work in these chapters establishes a new stepping stone for in vitro models of bone metastatic PCa, providing new tools for drug discovery and cancer research. Advisors/Committee Members: Farach-Carson, Mary C (advisor), Lwigale, Peter Y (advisor).

Subjects/Keywords: Prostate cancer; 3D models; bone metastases

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sablatura, L. K. (2020). Complex 3D Culture Models for the Study of Bone Metastatic Prostate Cancer. (Doctoral Dissertation). Rice University. Retrieved from http://hdl.handle.net/1911/108397

Chicago Manual of Style (16^th Edition):

Sablatura, Lindsey Kay. “Complex 3D Culture Models for the Study of Bone Metastatic Prostate Cancer.” 2020. Doctoral Dissertation, Rice University. Accessed March 08, 2021. http://hdl.handle.net/1911/108397.

MLA Handbook (7^th Edition):

Sablatura, Lindsey Kay. “Complex 3D Culture Models for the Study of Bone Metastatic Prostate Cancer.” 2020. Web. 08 Mar 2021.

Vancouver:

Sablatura LK. Complex 3D Culture Models for the Study of Bone Metastatic Prostate Cancer. [Internet] [Doctoral dissertation]. Rice University; 2020. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/1911/108397.

Council of Science Editors:

Sablatura LK. Complex 3D Culture Models for the Study of Bone Metastatic Prostate Cancer. [Doctoral Dissertation]. Rice University; 2020. Available from: http://hdl.handle.net/1911/108397

University of Oxford

4. Whitburn, Jessica. The role of metabolism in prostate cancer progression and bone metastases.

Degree: PhD, 2019, University of Oxford

URL: http://ora.ox.ac.uk/objects/uuid:37c06642-066c-4190-af02-62fe8db13e75 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.808259

► Prostate cancer (PCa) is the most common cancer in males in the Western world, and whilst treatment of localised disease is very effective, bone metastatic… (more)

▼ Prostate cancer (PCa) is the most common cancer in males in the Western world, and whilst treatment of localised disease is very effective, bone metastatic disease remains incurable and overall survival is only around 2-3 years. In view of this there is a need to identify novel therapeutics. Dysregulated cellular energetics is one of the new hallmarks of cancer, however the changes in cancer metabolism that occur when cancer metastasises remain relatively unexplored. The aim of this project was to identify the changes in PCa metabolism when it metastasises to the bone microenvironment, with the hope of identifying novel targets for advanced PCa therapeutics. Using a combination of in vitro metabolomic profiling of PCa/bone cell co-cultures, an in vivo mouse model of PCa bone disease and in silico analyses of patient data sets it was established that the bone metastatic site causes alterations in several metabolic pathways in PCa cells, including up-regulation of oxidative phosphorylation, the tricarboxylic acid cycle, and the pentose phosphate pathway (PPP). The PPP alterations were of interest as this pathway provides nucleotide precursors necessary for cellular proliferation, and is the main cellular source of NADPH, which is vital in cellular detoxification of potentially harmful free radicals. PPP enzymes were found to be more highly expressed in bone metastatic PCa cell lines compared to benign or non-bone metastatic cell lines, and expression of its rate limiting enzyme glucose-6-phosphate-dehydrogenase (G6PD) could be up-regulated by bone marrow stromal cells (BMSCs), suggesting that the bone microenvironment is driving this effect. In multiple patient data sets G6PD mRNA expression was elevated in metastatic samples, particularly bone metastatic samples, and expression was higher in castration resistant prostate cancer samples compared to hormone dependent. BMSCs were found to secrete high levels of interleukin-6 (IL-6), and blocking IL-6 was able to in part abrogate the up-regulation of G6PD, whilst recombinant IL-6 could induce G6PD up-regulation. BMSCs increased reactive oxygen species (ROS) in PCa cells and reduced the viability of non-bone metastatic cell lines. This was evident in vitro and in a xenograft mouse model. Pharmacological inhibition of G6PD further increased ROS levels, suggesting PCa up-regulates G6PD to counteract the high ROS induced by BMSCs. Pharmacological or genetic blockade of G6PD in PCa cells reduced their proliferation, inhibited cell migration, reduced expression of mesenchymal markers, decreased antioxidant levels, increased ROS levels, and increased sensitivity to chemotherapy. Overexpression of G6PD promoted PCa cell proliferation and increased antioxidant levels. In vivo, knockdown of G6PD expression in PCa cells could reduce tumour burden within bone. This work demonstrates for the first time that stromal cells of the metastatic environment drive changes in the metabolism of cancer cells that can promote their anti-oxidant abilities and increase their resistance to…

Subjects/Keywords: Prostate Cancer; Cancer Metabolism; Bone Metastases

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Whitburn, J. (2019). The role of metabolism in prostate cancer progression and bone metastases. (Doctoral Dissertation). University of Oxford. Retrieved from http://ora.ox.ac.uk/objects/uuid:37c06642-066c-4190-af02-62fe8db13e75 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.808259

Chicago Manual of Style (16^th Edition):

Whitburn, Jessica. “The role of metabolism in prostate cancer progression and bone metastases.” 2019. Doctoral Dissertation, University of Oxford. Accessed March 08, 2021. http://ora.ox.ac.uk/objects/uuid:37c06642-066c-4190-af02-62fe8db13e75 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.808259.

MLA Handbook (7^th Edition):

Whitburn, Jessica. “The role of metabolism in prostate cancer progression and bone metastases.” 2019. Web. 08 Mar 2021.

Vancouver:

Whitburn J. The role of metabolism in prostate cancer progression and bone metastases. [Internet] [Doctoral dissertation]. University of Oxford; 2019. [cited 2021 Mar 08]. Available from: http://ora.ox.ac.uk/objects/uuid:37c06642-066c-4190-af02-62fe8db13e75 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.808259.

Council of Science Editors:

Whitburn J. The role of metabolism in prostate cancer progression and bone metastases. [Doctoral Dissertation]. University of Oxford; 2019. Available from: http://ora.ox.ac.uk/objects/uuid:37c06642-066c-4190-af02-62fe8db13e75 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.808259

University of Edinburgh

5. Peramuhendige, Pushpabhani Prabha. Role of TRAF2/6 in tumour growth and bone metastases associated with breast cancer.

Degree: PhD, 2016, University of Edinburgh

URL: http://hdl.handle.net/1842/25800

► Tumour necrosis factor receptor associated factors (TRAFs) play a key role in signal transduction in mammalian cells. Several members of the TRAF family have been… (more)

▼ Tumour necrosis factor receptor associated factors (TRAFs) play a key role in signal transduction in mammalian cells. Several members of the TRAF family have been identified but only TRAF2 and TRAF6 are implicated in the regulation of both osteoclastic bone resorption and breast cancer. Here I studied the role of TRAF2 and TRAF6 in breast cancer induced osteoclastogenesis and osteolysis. I observed that TRAF2, but not TRAF6, is highly expressed in a highly metastatic bone-tropic clone of the human MDA-MB-231-BT (MDA-231-BT) breast cancer cells when compared to parental MDA-MB-231 (MDA-231) cells. Targeted knockdown of TRAF2, but not TRAF6, in both parental MDA-231 and bone-tropic MDA-231-BT breast cancer cells by siRNAs markedly reduced cell migration and significantly reduced the ability of these cells and their conditioned medium to induce osteoclast formation in RANKL stimulated bone marrow cultures. Encouraged by these data, I generated stable parental MDA-231 and bone-tropic MDA-231-BT breast cancer cell lines overexpressing TRAF2 using a retroviral approach. Then, I went on to show that overexpression of TRAF2 in parental MDA-231 cell line significantly stimulated directed cell migration and 3D invasion in vitro. Bone-tropic MDA-231-BT breast cancer cells over expressing TRAF2 or their conditioned medium were significantly effective in enhancing RANKL induced osteoclast formation in vitro. Mechanistic studies in parental MDA-231 and bone-tropic MDA-231-BT breast cancer cells revealed that over-expression of TRAF2 enhanced cell migration and osteoclastogenesis via a mechanism that involves the activation of the breast cancer oncogene IKKepsilon (IKKε) coupled with significant increase in levels of Vascular endothelial growth factor (VEGF). Ex vivo studies in human MDA-231-mouse calvaria organ co-cultures showed that conditioned medium obtained from MDA- 231 cells enhanced calvarial osteolysis. In vivo studies showed that overexpression of TRAF2 in the human breast cancer cells MDA-231 enhanced tumour incidence and tumour volume after orthotopic injection and exacerbated osteolysis after supracalvarial injection of conditioned medium from these cells. In conclusion, our studies showed that the TRAF2/IKK/VEGF axis in breast cancer cells regulates breast cancer cell motility in vitro, osteoclastogenesis in vitro and osteolysis ex vivo and in vivo. However, the role of TRAF2 in bone metastasis associated with breast cancer will require further in vivo investigation.

Subjects/Keywords: 616.99; TRAF2; bone; bone metastases; TRAFs; breast cancer

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Peramuhendige, P. P. (2016). Role of TRAF2/6 in tumour growth and bone metastases associated with breast cancer. (Doctoral Dissertation). University of Edinburgh. Retrieved from http://hdl.handle.net/1842/25800

Chicago Manual of Style (16^th Edition):

Peramuhendige, Pushpabhani Prabha. “Role of TRAF2/6 in tumour growth and bone metastases associated with breast cancer.” 2016. Doctoral Dissertation, University of Edinburgh. Accessed March 08, 2021. http://hdl.handle.net/1842/25800.

MLA Handbook (7^th Edition):

Peramuhendige, Pushpabhani Prabha. “Role of TRAF2/6 in tumour growth and bone metastases associated with breast cancer.” 2016. Web. 08 Mar 2021.

Vancouver:

Peramuhendige PP. Role of TRAF2/6 in tumour growth and bone metastases associated with breast cancer. [Internet] [Doctoral dissertation]. University of Edinburgh; 2016. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/1842/25800.

Council of Science Editors:

Peramuhendige PP. Role of TRAF2/6 in tumour growth and bone metastases associated with breast cancer. [Doctoral Dissertation]. University of Edinburgh; 2016. Available from: http://hdl.handle.net/1842/25800

Penn State University

6. McCarthy, Sarah Anne. A Role for TRPV6 Ion Channels in Prostate Cancer Bone Metastases.

Degree: 2012, Penn State University

URL: https://submit-etda.libraries.psu.edu/catalog/13790

► There are currently no effective therapeutic treatments to prevent prostate cancer (PCa) bone metastases. Identifying mechanisms that facilitate favorable PCa cell to bone interactions will… (more)

▼ There are currently no effective therapeutic treatments to prevent prostate cancer (PCa) bone metastases. Identifying mechanisms that facilitate favorable PCa cell to bone interactions will aid in the development of therapies to prevent bone metastases. The objective of this study was to identify a role for calcium and Transient Receptor Potential Vanilloid 6 (TRPV6) ion channels in the metastatic potential and early colonization of osteoblastic PCa cells to murine bone. We proposed that transient increases in serum calcium, following parathyroid hormone (PTH) 1-34 administration, confers a metastatic advantage to PCa cells in circulation, signaled partially via TRPV6 ion channels. To identify the effect of transient elevations in calcium on osteoblastic PCa cell metastatic potential, we employed heterotypic cell adhesion, transwell migration, and invasion assays. Observations from cell adhesion assays suggested that osteoblastic PCa cells increased adhesion to human bone marrow endothelial (hbmE) cells pre-treated with extracellular calcium. Studies suggested that increased extracellular calcium enhanced E-Selectin, VCAM-1 and ICAM-1 cell surface abundance on hbmE cells and that these molecules were partially responsible for increased heterotypic cell adhesion. Increased extracellular calcium also enhanced migration of osteoblastic PCa cell lines, in vitro. To identify the requirement for TRPV6 expression in osteoblastic PCa cell metastatic potential, we reduced TRPV6 expression in osteoblastic PCa cell lines. PCa cells with reduced levels of TRPV6 expression demonstrated slower proliferation rates and an impaired ability to adhere to and invade hbmE cells. Lastly, to identify a role for TRPV6 expression in early PCa cell colonization of murine bone, SCID/Beige mice were administered PTH 1-34 or vehicle, intermittently, then inoculated with PCa cells engineered to express reduced levels of TRPV6. Eight weeks post PCa cell inoculation, PCa cells were identified in long bones of 100% of animals administered PTH 1-34, relative to 20% of animals treated with vehicle. In contrast, PCa cells were identified in only 20% of the long bones of animals administered PTH 1-34, and then inoculated with PCa cells with reduced TRPV6 expression. Our observations support our hypothesis and suggest that calcium and TRPV6 may have a role in facilitating favorable PCa cell to bone interactions. Advisors/Committee Members: Ronald R Gomes Jr, Dissertation Advisor/Co-Advisor, Henry Joseph Donahue, Committee Member, Patricia Mc Laughlin, Committee Member, Andrea Manni, Committee Member, Andrea Marie Mastro, Committee Member.

Subjects/Keywords: Prostate cancer; TRPV6; parathyroid hormone; osteoblastic; calcium; bone metastases; invasion; adhesion

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

McCarthy, S. A. (2012). A Role for TRPV6 Ion Channels in Prostate Cancer Bone Metastases. (Thesis). Penn State University. Retrieved from https://submit-etda.libraries.psu.edu/catalog/13790

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

McCarthy, Sarah Anne. “A Role for TRPV6 Ion Channels in Prostate Cancer Bone Metastases.” 2012. Thesis, Penn State University. Accessed March 08, 2021. https://submit-etda.libraries.psu.edu/catalog/13790.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

McCarthy, Sarah Anne. “A Role for TRPV6 Ion Channels in Prostate Cancer Bone Metastases.” 2012. Web. 08 Mar 2021.

Vancouver:

McCarthy SA. A Role for TRPV6 Ion Channels in Prostate Cancer Bone Metastases. [Internet] [Thesis]. Penn State University; 2012. [cited 2021 Mar 08]. Available from: https://submit-etda.libraries.psu.edu/catalog/13790.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

McCarthy SA. A Role for TRPV6 Ion Channels in Prostate Cancer Bone Metastases. [Thesis]. Penn State University; 2012. Available from: https://submit-etda.libraries.psu.edu/catalog/13790

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

7. Goguet-Surmenian, Émilie. Étude préclinique d’Immunothérapie des métastases osseuses expérimentales par la fractalkine : Preclinical study of immunotherapy of experimental bone metastases by the fractalkine chemokine.

Degree: Docteur es, Interactions moléculaires et cellulaires, 2014, Nice

URL: http://www.theses.fr/2014NICE4131

►

Les métastases osseuses représentent un enjeu majeur de santé publique en raison de leur impact négatif sur la qualité de vie des patients mais également… (more)

▼

Les métastases osseuses représentent un enjeu majeur de santé publique en raison de leur impact négatif sur la qualité de vie des patients mais également en raison de l’absence de traitements curatif. De nouvelles pistes thérapeutiques sont explorées dont l’immunothérapie anti-cancéreuse. En tant que principales responsables du recrutement leucocytaire, les chimiokines représentent des outils potentiels dans cette approche thérapeutique. La chimiokine fractalkine (CX3CL1) est impliquée dans de nombreux mécanismes physiologiques et pathologiques, dont le métabolisme osseux, la réponse immunitaire anti-tumorale mais également l’adressage et le développement tumoral, et ce de manière différentielle selon la forme considérée de cette chimiokine. En effet, CX3CL1 a la particularité d’exister sous deux formes : membranaire atypique (propriétés d’adhésion cellulaire) et soluble, typique des chimiokines (propriétés de chimioattraction). La mise en place d’un modèle syngénique murin de métastases osseuses expérimentales de carcinome pulmonaire nous a permis d’étudier l’effet de la forme soluble de CX3CL1 sur le développement métastatique en site osseux. L’expression ectopique de CX3CL1 soluble dans les cellules tumorales pulmonaires a conduit à une diminution de leur potentiel tumorigénique, une diminution de la résorption osseuse associée à une modification du ratio OPG/RANKL en faveur d’un phénotype ostéoblastique et à une modification du recrutement leucocytaire intratumoral en faveur d’une réponse immunitaire anti-tumorale. Outre l’importance de CX3CL1 dans le remodelage osseux, ce travail souligne le rôle essentiel du microenvironnement immunitaire dans la progression tumorale. Dans ce contexte, la forme soluble de CX3CL1 pourrait représenter un outil prometteur dans l’arsenal thérapeutique des métastases osseuses

Bone metastases represent a major public health issue due to their negative impact on patient’s quality of life as well as the current lack of curative treatment. New therapeutic leads are being investigated, among which is the anti-cancer immunotherapy. As the main molecules responsible for leukocyte recruitment, chemokines appear as potential tools for this therapeutic approach. The chemokine fractalkine (CX3CL1) is implicated in numerous physiological and pathological mechanisms, including bone metabolism, antitumor immune response as well as tumor homing and proliferation, in a differential manner depending on the considered form of CX3CL1. Indeed, the particularity of CX3CL1 is that it can exist under two forms: an atypical membrane-bound form (strong cellular adhesion) and a chemokine typical soluble form (chemoattraction). The development of a mouse syngeneic model of lung cancer experimental bone metastases allowed us to study the effect of the soluble CX3CL1 on metastatic development in a skeletal location. The ectopic expression of soluble CX3CL1 in the lung cancer cells led to a decrease of their tumorigenic potential, a decrease of bone resorption associated with a shift of the OPG/RANKL ratio…

Advisors/Committee Members: Schmid-Antomarchi, Heidy (thesis director).

Subjects/Keywords: Cancer; Immunothérapie; Fractalkine; Métastases osseuses; Cancer; Immunotherapy; Fractalkine; Bone metastases

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Goguet-Surmenian, �. (2014). Étude préclinique d’Immunothérapie des métastases osseuses expérimentales par la fractalkine : Preclinical study of immunotherapy of experimental bone metastases by the fractalkine chemokine. (Doctoral Dissertation). Nice. Retrieved from http://www.theses.fr/2014NICE4131

Chicago Manual of Style (16^th Edition):

Goguet-Surmenian, Émilie. “Étude préclinique d’Immunothérapie des métastases osseuses expérimentales par la fractalkine : Preclinical study of immunotherapy of experimental bone metastases by the fractalkine chemokine.” 2014. Doctoral Dissertation, Nice. Accessed March 08, 2021. http://www.theses.fr/2014NICE4131.

MLA Handbook (7^th Edition):

Goguet-Surmenian, Émilie. “Étude préclinique d’Immunothérapie des métastases osseuses expérimentales par la fractalkine : Preclinical study of immunotherapy of experimental bone metastases by the fractalkine chemokine.” 2014. Web. 08 Mar 2021.

Vancouver:

Goguet-Surmenian �. Étude préclinique d’Immunothérapie des métastases osseuses expérimentales par la fractalkine : Preclinical study of immunotherapy of experimental bone metastases by the fractalkine chemokine. [Internet] [Doctoral dissertation]. Nice; 2014. [cited 2021 Mar 08]. Available from: http://www.theses.fr/2014NICE4131.

Council of Science Editors:

Goguet-Surmenian �. Étude préclinique d’Immunothérapie des métastases osseuses expérimentales par la fractalkine : Preclinical study of immunotherapy of experimental bone metastases by the fractalkine chemokine. [Doctoral Dissertation]. Nice; 2014. Available from: http://www.theses.fr/2014NICE4131

University of Toronto

8. Pezeshki, Padina. Bone Targeted Radiofrequency Ablation (RFA) Electrodes for the Treatment of Appendicular and Vertebral Metastases.

Degree: PhD, 2014, University of Toronto

URL: http://hdl.handle.net/1807/73797

► Bone metastases, an unfortunate and frequent occurrence in cancer, can result in skeletal related events, including pain, pathologic fractures, and hypercalcemia. Treatment strategies, such as… (more)

▼ Bone metastases, an unfortunate and frequent occurrence in cancer, can result in skeletal related events, including pain, pathologic fractures, and hypercalcemia. Treatment strategies, such as surgery and/or radiation therapy, can be limited by invasiveness, maximum dose levels, and radio-resistivity. In this context, image-guided minimally invasive thermal treatment modalities such as radiofrequency ablation (RFA) have gained interest in the treatment of bone metastases. RFA conducts an alternating current through a probe placed within the tumour, resulting in ionic excitation of cells and frictional heating. RFA is reliant upon thermal and conductive properties of the tissue and leads to coagulative necrosis. Current technology developed and tested in soft tissues is limited by carbonization, small and unpredictable zones of ablation, particularly when used in bone. The lower conductive properties of bone tissue and proximity of bone to critical structures further challenge RFA application. This thesis focuses on design and evaluation of two novel bone-targeted RFA electrodes, a bipolar cooled RF (BCRF) and a solenoid-shaped (Bone Coil) RF probe, to improve the size and efficacy of RFA in bone. RFA was evaluated using healthy porcine and diseased lapine models with outcomes assessed through Magnetic Resonance Imaging (MRI) and histologic analysis of bone and tumour tissue. A cadaveric model was used to evaluate the role of RFA on spinal stability alone and in combination with vertebroplasty. Both BCRF and Bone Coil RF ablation were safe and effective in the spine. T2-weighted and contrast-enhanced T1-weighted MRI sequences two weeks post treatment were found to be most effective for image-based therapeutic evaluation. BCRF ablation yielded an eight-fold reduction in tumour volume in the rabbit femur. Treatment necrotized osteoblasts and osteoclasts comprehensively, whereas osteocytes were found to be more resilient to RFA. New bone formation and remodelling was observed at the ablation zone periphery. RFA alone led to reduced vertebral stability, but a restoration of strength and stability comparable to healthy levels was achieved when RFA treatment was combined with cement injection localized into the posterior portion of the vertebral body. Overall, this work motivates the future use of bone-targeted RF technology in the treatment of skeletal metastases. Advisors/Committee Members: Whyne, Cari M., Yee, Albert J., Biomedical Engineering.

Subjects/Keywords: Bone metastases; Cancer; Histology; Imaging; Medical device; Radiofrequency ablation; 0541

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Pezeshki, P. (2014). Bone Targeted Radiofrequency Ablation (RFA) Electrodes for the Treatment of Appendicular and Vertebral Metastases. (Doctoral Dissertation). University of Toronto. Retrieved from http://hdl.handle.net/1807/73797

Chicago Manual of Style (16^th Edition):

Pezeshki, Padina. “Bone Targeted Radiofrequency Ablation (RFA) Electrodes for the Treatment of Appendicular and Vertebral Metastases.” 2014. Doctoral Dissertation, University of Toronto. Accessed March 08, 2021. http://hdl.handle.net/1807/73797.

MLA Handbook (7^th Edition):

Pezeshki, Padina. “Bone Targeted Radiofrequency Ablation (RFA) Electrodes for the Treatment of Appendicular and Vertebral Metastases.” 2014. Web. 08 Mar 2021.

Vancouver:

Pezeshki P. Bone Targeted Radiofrequency Ablation (RFA) Electrodes for the Treatment of Appendicular and Vertebral Metastases. [Internet] [Doctoral dissertation]. University of Toronto; 2014. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/1807/73797.

Council of Science Editors:

Pezeshki P. Bone Targeted Radiofrequency Ablation (RFA) Electrodes for the Treatment of Appendicular and Vertebral Metastases. [Doctoral Dissertation]. University of Toronto; 2014. Available from: http://hdl.handle.net/1807/73797

Leiden University

9. Bollen, L. Predicting survival in patients with spinal bone metastases.

Degree: 2019, Leiden University

URL: http://hdl.handle.net/1887/78468

► An accurate estimation of survival is essential in selecting the appropriate treatment for patients suffering from symptomatic spinal bone metastases. This thesis describes the… (more)

Subjects/Keywords: Spinal Bone Metastases Survival

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bollen, L. (2019). Predicting survival in patients with spinal bone metastases. (Doctoral Dissertation). Leiden University. Retrieved from http://hdl.handle.net/1887/78468

Chicago Manual of Style (16^th Edition):

Bollen, L. “Predicting survival in patients with spinal bone metastases.” 2019. Doctoral Dissertation, Leiden University. Accessed March 08, 2021. http://hdl.handle.net/1887/78468.

MLA Handbook (7^th Edition):

Bollen, L. “Predicting survival in patients with spinal bone metastases.” 2019. Web. 08 Mar 2021.

Vancouver:

Bollen L. Predicting survival in patients with spinal bone metastases. [Internet] [Doctoral dissertation]. Leiden University; 2019. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/1887/78468.

Council of Science Editors:

Bollen L. Predicting survival in patients with spinal bone metastases. [Doctoral Dissertation]. Leiden University; 2019. Available from: http://hdl.handle.net/1887/78468

10. Dijkstra, Sander. Pathological fractures of long bones due to bone metastases.

Degree: 1997, Erasmus University Medical Center

URL: http://hdl.handle.net/1765/18576

Subjects/Keywords: bone cancer; bone metastases; bone tumors; orthopedics; pathological fractures

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Dijkstra, S. (1997). Pathological fractures of long bones due to bone metastases. (Doctoral Dissertation). Erasmus University Medical Center. Retrieved from http://hdl.handle.net/1765/18576

Chicago Manual of Style (16^th Edition):

Dijkstra, Sander. “Pathological fractures of long bones due to bone metastases.” 1997. Doctoral Dissertation, Erasmus University Medical Center. Accessed March 08, 2021. http://hdl.handle.net/1765/18576.

MLA Handbook (7^th Edition):

Dijkstra, Sander. “Pathological fractures of long bones due to bone metastases.” 1997. Web. 08 Mar 2021.

Vancouver:

Dijkstra S. Pathological fractures of long bones due to bone metastases. [Internet] [Doctoral dissertation]. Erasmus University Medical Center; 1997. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/1765/18576.

Council of Science Editors:

Dijkstra S. Pathological fractures of long bones due to bone metastases. [Doctoral Dissertation]. Erasmus University Medical Center; 1997. Available from: http://hdl.handle.net/1765/18576

Universiteit Utrecht

11. Huisman, M. MR-HIFU for treatment of painful bone metastases.

Degree: 2014, Universiteit Utrecht

URL: http://dspace.library.uu.nl:8080/handle/1874/301530

► Purpose: Bone metastases are the most common cause of pain in cancer patients. Palliative radiotherapy is effective in relieving pain in bone metastases and has… (more)

▼ Purpose: Bone metastases are the most common cause of pain in cancer patients. Palliative radiotherapy is effective in relieving pain in bone metastases and has been the standard of care for decades. Nevertheless, an increasing amount of patients is insufficiently palliated by radiotherapy alone. MRI-guided High Intensity Focused Ultrasound (MR-HIFU) has recently been proposed as a novel noninvasive ablative treatment option for metastatic bone pain. To translate MR-HIFU for painful bone metastases to the clinic, several steps have to be taken. First, a reference value for a new treatment modality needs to be established as in clinical practice patients with unrelieved metastatic bone pain after radiotherapy commonly receive repeat radiotherapy (reirradiation), although its effectiveness is unknown. Then, early evaluation of MR-HIFU on safety, feasibility and effectiveness may provide rationale for larger studies, needed to determine the clinical value of MR-HIFU for treatment of patients with painful bone metastases. Materials and Methods: In part I, we conducted a meta-analysis (7 studies, n=527) and a 10-year retrospective cohort study (n=247) to determine the effectiveness of reirradiation for painful bone metastases and to identify predictors for response. Also, a matched case-control study (n=114) was conducted to investigate the association between spinal instability and radiotherapy outcome. In part II, a literature review on MR-HIFU in oncology is described. A feasibility study (n=11) on MR-HIFU for patients with painful bone metastases was conducted in pain response and complications were evaluated. Lastly, an international evidence-based consensus on MR-HIFU for painful bone metastases was established among experts in the field to determine current treatment goals, indications and research priorities. Results: In the meta-analysis an overall pain response rate of 58% of reirradiated patients was found. In the retrospective cohort-study an overall response rate of 43% in an intention-to-treat analysis and 66% in a per-protocol analysis was observed. Patients who showed beneficial response to initial radiation were more likely to respond well to reirradiation. Patients previously treated with systemic therapy were less likely to respond to reirradiation. The matched case-control study showed that patients with increased spinal instability were more likely to be retreated after radiotherapy. In the feasibility study on MR-HIFU for painful bone metastases, no major adverse events were observed and pain response was noted in 67% of patients. The main statements of the consensus were that MR-HIFU is currently a secondary palliative treatment option, and its role in primary treatment of bone metastases as a stand-alone treatment or in combination with radiotherapy needs to be investigated in a three-armed randomized controlled trial. Conclusions: Overall, the work is this thesis shows there is a clinical need for additional palliative treatments for metastatic bone pain beyond radiotherapy and… Advisors/Committee Members: Bosch, M.A.A.J. van den, Vulpen, M. van, Verkooijen, H.M., Bartels, L.W..

Subjects/Keywords: Geneeskunde; radiology; radiotherapy; focused utlrasound; MRI; oncology; palliative medicine; imaging; bone metastases; cancer

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Huisman, M. (2014). MR-HIFU for treatment of painful bone metastases. (Doctoral Dissertation). Universiteit Utrecht. Retrieved from http://dspace.library.uu.nl:8080/handle/1874/301530

Chicago Manual of Style (16^th Edition):

Huisman, M. “MR-HIFU for treatment of painful bone metastases.” 2014. Doctoral Dissertation, Universiteit Utrecht. Accessed March 08, 2021. http://dspace.library.uu.nl:8080/handle/1874/301530.

MLA Handbook (7^th Edition):

Huisman, M. “MR-HIFU for treatment of painful bone metastases.” 2014. Web. 08 Mar 2021.

Vancouver:

Huisman M. MR-HIFU for treatment of painful bone metastases. [Internet] [Doctoral dissertation]. Universiteit Utrecht; 2014. [cited 2021 Mar 08]. Available from: http://dspace.library.uu.nl:8080/handle/1874/301530.

Council of Science Editors:

Huisman M. MR-HIFU for treatment of painful bone metastases. [Doctoral Dissertation]. Universiteit Utrecht; 2014. Available from: http://dspace.library.uu.nl:8080/handle/1874/301530

Johannes Gutenberg Universität Mainz

12. Hackl, Norman J. Die Rolle des Fibronektins bei der Entstehung und dem Wachstum von Tumoren.

Degree: 2010, Johannes Gutenberg Universität Mainz

URL: http://ubm.opus.hbz-nrw.de/volltexte/2010/2204/

►

Diese Arbeit befasst sich mit der Rolle des Fibronektins für die Entstehung und des Wachstums von Knochenmetastasen. rnrnTumorzellspezifische Faktoren bereiten entfernte Gewebe auf die Besiedelung… (more)

▼

Diese Arbeit befasst sich mit der Rolle des Fibronektins für die Entstehung und des Wachstums von Knochenmetastasen. rnrnTumorzellspezifische Faktoren bereiten entfernte Gewebe auf die Besiedelung durch disseminierte Tumorzellen vor. Dabei wird Fibronektin im Bereich der prämetastatischen Nische vermehrt gebildet. Dies führte zu der Annahme, dass Fibronektin eine wichtige Rolle bei der Entstehung von Tumoren einnimmt. Um die Bedeutung des Fibronektins bezüglich des Metastasierungsprozesses näher zu charakterisieren, wurde dieses im Bereich der vaskulären Nische über das Cre/loxP-System ausgeschaltet. Die Inaktivierung von zirkulierendem Fibronektin und Knochenmarks-Fibronektin in vivo hatte ein verlangsamtes Tumorwachstum zur Folge, welches auf eine um 22% verminderte Angiogenese zurückzuführen war. Im Gegensatz dazu beeinträchtigte die Ausschaltung des Osteoblasten-Fibronektins lediglich die frühen Entwicklungsstadien der Tumore. Diese Beobachtungen könnten einerseits mit der eingeschränkten Funktionsweise der Osteoblasten in Abwesenheit von Fibronektin erklärt werden, andererseits könnte der Einfluss auf das Fehlen osteoblastenspezifischer Fibronektin-Isoformen zurückgeführt werden, die die Metastasierung, Zelladhäsion, Proliferation und Motilität von Tumorzellen erhöhen. rnrnDie Deletion des Tumorzell-Fibronektins hatte eine durchschnittlich um 60% reduzierte Anzahl gebildeter Metastasen, ein eingeschränktes Tumorwachstum, hervorgerufen durch eine um 37% verminderte Blutgefäßanzahl, und letztendlich eine dreifache Verlängerung der mittleren Überlebensraten zur Folge. Die kombinierte Ausschaltung von lokalem Fibronektin und Tumorzell-Fibronektin vermochte den Einfluss auf die Etablierung und das Wachstum der Tumore zu verstärken. rnrnEin Drittel der Tiere, denen Metastasen induziert wurden, zeigten eine spontane Rückbildung der Tumore, ohne dass eine medizinische Intervention erfolgte. Dabei wurde zwischen einer kompletten Regression, bei der eine vollständige Rückbildung aller Tumore beobachtet werden konnte, und einer partiellen Regression, von der nur einzelne Tumore betroffen waren, unterschieden. Die spontane Regression war altersabhängig und trat 8-17 Wochen im Anschluss an die Applikation der Tumorzellen auf. Die vollständige Rückbildung der osteolytischen Knochenläsionen war mit dem Heilungsprozess des Knochengewebes verbunden, der sich in einer Verdichtung der Knochensubstanz äußerte. Erste Ergebnisse lieferten Hinweise darauf, dass die spontane Tumorregression auf eine mögliche Beteiligung von Granulozyten zurückzuführen war.rnrnZusammenfassend zeigten unsere Untersuchungen, dass sowohl Fibronektin der Mikroumgebung als auch Tumorzell-Fibronektin die Entwicklung und das Wachstum von Tumoren beeinträchtigte. Diese Arbeit lieferte erste Hinweise auf die Existenz eines sehr effektiven Mechanismus, der in Zusammenhang mit Fibronektin steht und dazu in der Lage ist, Tumorzellen selbst bei fortgeschrittenen Krebserkrankungen zu beseitigen. rn

This PhD thesis discusses the role of fibronectin in the…

Subjects/Keywords: Fibronektin, Knochenmetastasen, Biolumineszenz-Bildgebung, Angiogenese; fibronectin, bone metastases, bioluminescence imaging, angiogenesis; Life sciences

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Hackl, N. J. (2010). Die Rolle des Fibronektins bei der Entstehung und dem Wachstum von Tumoren. (Doctoral Dissertation). Johannes Gutenberg Universität Mainz. Retrieved from http://ubm.opus.hbz-nrw.de/volltexte/2010/2204/

Chicago Manual of Style (16^th Edition):

Hackl, Norman J. “Die Rolle des Fibronektins bei der Entstehung und dem Wachstum von Tumoren.” 2010. Doctoral Dissertation, Johannes Gutenberg Universität Mainz. Accessed March 08, 2021. http://ubm.opus.hbz-nrw.de/volltexte/2010/2204/.

MLA Handbook (7^th Edition):

Hackl, Norman J. “Die Rolle des Fibronektins bei der Entstehung und dem Wachstum von Tumoren.” 2010. Web. 08 Mar 2021.

Vancouver:

Hackl NJ. Die Rolle des Fibronektins bei der Entstehung und dem Wachstum von Tumoren. [Internet] [Doctoral dissertation]. Johannes Gutenberg Universität Mainz; 2010. [cited 2021 Mar 08]. Available from: http://ubm.opus.hbz-nrw.de/volltexte/2010/2204/.

Council of Science Editors:

Hackl NJ. Die Rolle des Fibronektins bei der Entstehung und dem Wachstum von Tumoren. [Doctoral Dissertation]. Johannes Gutenberg Universität Mainz; 2010. Available from: http://ubm.opus.hbz-nrw.de/volltexte/2010/2204/

Johannes Gutenberg Universität Mainz

13. Meckel, Marian. Macrocyclic bisphosphonates for PET-diagnosis and endoradiotherapy of bone metastases.

Degree: 2014, Johannes Gutenberg Universität Mainz

URL: http://ubm.opus.hbz-nrw.de/volltexte/2014/3908/

►

Die Fallzahlen von Prostata- und Brustkrebs nehmen aktuell die Spitzenplätze bei Krebserkrankungen weltweit ein. Eine schwerwiegende Folge dieser Erkrankung stellen Metastasierungen in das Knochengewebe dar,… (more)

▼

Die Fallzahlen von Prostata- und Brustkrebs nehmen aktuell die Spitzenplätze bei Krebserkrankungen weltweit ein. Eine schwerwiegende Folge dieser Erkrankung stellen Metastasierungen in das Knochengewebe dar, welche zu einer dramatischen Verschlechterung des Allgemeinzustandes und der Lebensqualität des Patienten führen. Die Symptome sind gekennzeichnet durch enorme Schmerzen in Kombination mit osteoblastischen und osteolytischen Knochenveränderungen, bis hin zu Frakturen und spinalen Kompressionssyndromen, sowie einer metabolischen Hypercalcaemie.rnBei der Diagnose und Therapie nehmen verschiedene Radiopharmaka eine Schlüsselrolle ein. Konjugate aus makrozyklischen Chelatoren und knochenaffinen Bisphosphonaten stellen ein geeignetes Mittel dar als so genannte Theranostika, die Diagnose und Therapie in einem Molekül vereinen. Hierbei konnten mit dem Generator basierenden PET-Nuklid 68Ga(III) und dem Therapienuklid 177Lu(III) erste Erfolge mit der Verbindung BPAMD am Patienten erzielt werden. Im Rahmen der vorliegenden Arbeit ist es gelungen, die pharmakologischen Eigenschaften der BPAMD-Leitstruktur weiter zu optimieren und neue Derivate erfolgreich zu synthetisieren. Diese zeichneten sich durch eine erhöhte Knochenaffinität und eines besseren ´target to background´ Verhältnisses aus. Im Zuge der Derivatisierung ist es außerdem gelungen, erfolgreich eine Substanz darzustellen, welche über eine gesteigerte Blutretention verfügt und die letztendlich die Bioverfügbarkeit des Tracers erhöhte. Verbindungen solchen Typs können zu einem besseren Tumor zu gesundem Knochen Verhältnis beitragen und eventuell einen höheren Therapieerfolg erzielen. Eines dieser neuen vielversprechenden Bisphosphonate, [68Ga]NO2APBP konnte innerhalb einer klinischen Phase 0 bzw. I sein großes Potential als Diagnostikum zur Erfassung von Skelettmetastasen unter Beweis stellen. Innerhalb einer Testreihe mit 12 Patienten wurde eine hohe diagnostische Übereinstimmung mit dem Goldstandard 18F-Fluorid erreicht. In ausgesuchten Metastasen konnte sogar eine höhere Tracer-Aufnahme erzielt werden.rnIn Zukunft können makrozyklische Bisphosphonate eine wichtige Rolle bei der palliativen Schmerztherapie von Knochenmetastasen einnehmen. rn

Prostate and breast cancer are high rated in the numbers of cancer cases worldwide. The serious consequence of this disease is the metastatic spread of the cancer into the bones. It is associated with severe bone pain, spinal cord compression, skeletal fractures and a metabolic hypercalceamie. Finally, the symptoms reduce the patients quality of life dramatically.rnRadiopharmaceuticals play a key role in the assessment and therapy of this disease. Conjugates of macrocyclic chelates and bone affine bisphosphonates are an appropriate means, as so called theranostics, to unite diagnosis and therapy in one molecule. In this connection the generator based PET-nuclide 68Ga(III) and the therapy nuclide 177Lu(III) showed promising first results with BPAMD in initial patient studies. For both trivalent radiometals, new derivatives…

Subjects/Keywords: Bisphosphonate, Bone Metastases, Ga-68, PET, Lu-177; Chemistry and allied sciences

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Meckel, M. (2014). Macrocyclic bisphosphonates for PET-diagnosis and endoradiotherapy of bone metastases. (Doctoral Dissertation). Johannes Gutenberg Universität Mainz. Retrieved from http://ubm.opus.hbz-nrw.de/volltexte/2014/3908/

Chicago Manual of Style (16^th Edition):

Meckel, Marian. “Macrocyclic bisphosphonates for PET-diagnosis and endoradiotherapy of bone metastases.” 2014. Doctoral Dissertation, Johannes Gutenberg Universität Mainz. Accessed March 08, 2021. http://ubm.opus.hbz-nrw.de/volltexte/2014/3908/.

MLA Handbook (7^th Edition):

Meckel, Marian. “Macrocyclic bisphosphonates for PET-diagnosis and endoradiotherapy of bone metastases.” 2014. Web. 08 Mar 2021.

Vancouver:

Meckel M. Macrocyclic bisphosphonates for PET-diagnosis and endoradiotherapy of bone metastases. [Internet] [Doctoral dissertation]. Johannes Gutenberg Universität Mainz; 2014. [cited 2021 Mar 08]. Available from: http://ubm.opus.hbz-nrw.de/volltexte/2014/3908/.

Council of Science Editors:

Meckel M. Macrocyclic bisphosphonates for PET-diagnosis and endoradiotherapy of bone metastases. [Doctoral Dissertation]. Johannes Gutenberg Universität Mainz; 2014. Available from: http://ubm.opus.hbz-nrw.de/volltexte/2014/3908/

Freie Universität Berlin

14. Börnert, Katja. Der Einfluss von Interleukin-6 Rezeptor Antikörpern auf Knochenmetastasen des Mammakarzinoms.

Degree: 2015, Freie Universität Berlin

URL: https://refubium.fu-berlin.de/handle/fub188/12630

► Das pleiotrope, für seine proinflammatorischen Eigenschaften bekannte, Zytokin Interleukin-6 (IL-6) weist zudem auch tumorprogressive Eigenschaften auf und übt einen Einfluss auf die Induktion und die… (more)

▼ Das pleiotrope, für seine proinflammatorischen Eigenschaften bekannte, Zytokin Interleukin-6 (IL-6) weist zudem auch tumorprogressive Eigenschaften auf und übt einen Einfluss auf die Induktion und die Aufrechterhaltung der Knochenresorption in osteolytischen Metastasen des Mammakarzinoms aus. In vorhergehenden Studien konnte gezeigt werden, dass Patientinnen mit metastasiertem Mammakarzinom, welche einen hohen IL-6-Serumspiegel aufweisen, sowohl ein höheres Risiko für weitere Krankheitsprogression, vermehrte Metastasen als auch eine generell schlechtere Prognose haben. Dies könnte einerseits an direkten Effekten von IL-6 auf die Tumorzellen liegen, welche zu einer augmentierten Zellproliferation und einer Hemmung der Apoptose führen, als auch an einer IL-6-induzierten vermehrten Knochenresorption mit nachfolgender Freisetzung von Wachstumsfaktoren aus dem ossären Kompartiment, welche letztlich auf die Tumorzellen im Umfeld wirken. In dieser Studie wurde der anti-humane IL-6 Rezeptor Antikörper (IL-6R mAb) Tocilizumab als auch der anti-murine IL-6R mAb MR16-1 in einem murinen Xenograftmodel getestet. Ziel der Studie war es die Effekte der jeweiligen Antikörperbehandlung auf die Tumorprogression und den Grad der tumorbedingten Osteolyse zu definieren. Zellen der humanen östrogenrezeptor-negativen Mammakarzinomzelllinie MDA- MB-231 wurden in Tibiae von athymischen Mäusen injiziert und die Tiere daraufhin mit den jeweiligen Antikörpern oder Placebo behandelt. Um die IL-6 Signaltransduktion in den humanen Mammakarzinomzellen zu blockieren, wurde eine Gruppe von Mäusen regelmässig mit Tocilizumab behandelt, wohingegen einer anderen Gruppe MR16-1 injiziert wurden. Weiterhin untersuchten wir den Effekt der Kombination von beiden Antikörperbehandlungen. Um den Verlauf der Entwicklung von osteolytischen Knochenmetastasen zu dokumentieren, wurden regelmässig radiologische Untersuchungen der Tibiae angefertigt. Endpunktanalysen zielten auf die histologische und immunhistochemische Analyse der Knochenmorphologie und der Tumorbiologie ab. Des Weiteren wurde in einem in vitro Experiment der Effekt von Tocilizumab auf die Expression von humaner IL-6 und humaner IL-6-Rezeptor mRNA und die Sekretion von humanem IL-6 durch MDA-Mb 231 Zellen untersucht. Hierbei stellte sich vor allem die Frage, ob ein autokriner feed-forward Mechanismus nach Aktivierung von IL-6 Rezeptoren in MDA-MB 231 Zellen existiert. Die Behandlung athymischer Mäuse mit Tocilizumab als auch mit MR16-1 führte zu einer Verminderung der Progression von osteolytischen Mammakarzinommetastasen. Hierbei wurde nicht nur der Grad der Knochenresorption verändert, sondern auch die Tumorbiologie der humanen Mammakarzinomzellen im Hinblick auf eine reduzierte Rate an proliferierenden und eine erhöhte Rate an apoptotischen Tumorzellen. Die Kombination beider Antikörperbehandlungen zeigte geringere Effekte als die Behandlung mit den einzelnen Antikörpern. Humane Mammakarzinomzellen, welche in vitro mit Tocilizumab behandelt wurden, zeigten eine reduzierte Rate an IL-6 und IL-6R… Advisors/Committee Members: [email protected] (contact), w (gender), N.N. (firstReferee), N.N. (furtherReferee).

Subjects/Keywords: Interleukin-6; breast cancer; bone metastases; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Börnert, K. (2015). Der Einfluss von Interleukin-6 Rezeptor Antikörpern auf Knochenmetastasen des Mammakarzinoms. (Thesis). Freie Universität Berlin. Retrieved from https://refubium.fu-berlin.de/handle/fub188/12630

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Börnert, Katja. “Der Einfluss von Interleukin-6 Rezeptor Antikörpern auf Knochenmetastasen des Mammakarzinoms.” 2015. Thesis, Freie Universität Berlin. Accessed March 08, 2021. https://refubium.fu-berlin.de/handle/fub188/12630.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Börnert, Katja. “Der Einfluss von Interleukin-6 Rezeptor Antikörpern auf Knochenmetastasen des Mammakarzinoms.” 2015. Web. 08 Mar 2021.

Vancouver:

Börnert K. Der Einfluss von Interleukin-6 Rezeptor Antikörpern auf Knochenmetastasen des Mammakarzinoms. [Internet] [Thesis]. Freie Universität Berlin; 2015. [cited 2021 Mar 08]. Available from: https://refubium.fu-berlin.de/handle/fub188/12630.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Börnert K. Der Einfluss von Interleukin-6 Rezeptor Antikörpern auf Knochenmetastasen des Mammakarzinoms. [Thesis]. Freie Universität Berlin; 2015. Available from: https://refubium.fu-berlin.de/handle/fub188/12630

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

15. CHEN XIULI. A STUDY ON STRUCTURAL, VISCOELASTIC PROPERTY AND OSTEOBLAST CHANGES IN OSTEOLYTIC METASTASES.

Degree: 2012, National University of Singapore

URL: http://scholarbank.nus.edu.sg/handle/10635/38753

Subjects/Keywords: Osteoblast; bone microstructure; viscoelasticity; osteolytic metastases

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

XIULI, C. (2012). A STUDY ON STRUCTURAL, VISCOELASTIC PROPERTY AND OSTEOBLAST CHANGES IN OSTEOLYTIC METASTASES. (Thesis). National University of Singapore. Retrieved from http://scholarbank.nus.edu.sg/handle/10635/38753

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

XIULI, CHEN. “A STUDY ON STRUCTURAL, VISCOELASTIC PROPERTY AND OSTEOBLAST CHANGES IN OSTEOLYTIC METASTASES.” 2012. Thesis, National University of Singapore. Accessed March 08, 2021. http://scholarbank.nus.edu.sg/handle/10635/38753.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

XIULI, CHEN. “A STUDY ON STRUCTURAL, VISCOELASTIC PROPERTY AND OSTEOBLAST CHANGES IN OSTEOLYTIC METASTASES.” 2012. Web. 08 Mar 2021.

Vancouver:

XIULI C. A STUDY ON STRUCTURAL, VISCOELASTIC PROPERTY AND OSTEOBLAST CHANGES IN OSTEOLYTIC METASTASES. [Internet] [Thesis]. National University of Singapore; 2012. [cited 2021 Mar 08]. Available from: http://scholarbank.nus.edu.sg/handle/10635/38753.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

XIULI C. A STUDY ON STRUCTURAL, VISCOELASTIC PROPERTY AND OSTEOBLAST CHANGES IN OSTEOLYTIC METASTASES. [Thesis]. National University of Singapore; 2012. Available from: http://scholarbank.nus.edu.sg/handle/10635/38753

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ)

16. Siampanopoulou, Maria. Η διερεύνηση των παραγόντων αύξησης και αγγειογένεσης σε ασθενείς με καρκίνο του προστάτη με ή χωρίς οστικές μεταστάσεις: συσχέτιση με καρκινικούς δείκτες και απεικονιστικά ευρήματα.

Degree: 2014, Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ)

URL: http://hdl.handle.net/10442/hedi/36948

► Prostate cancer (PCa) is the most common malignancy in males in the United States and Western Europe. PSA and bone scans are important modalities for… (more)

▼ Prostate cancer (PCa) is the most common malignancy in males in the United States and Western Europe. PSA and bone scans are important modalities for evaluating and following disease progression. Recently, it was confirmed that angiogenesis plays an important role in the development and spread of a variety of human cancers, including PCa. The aim of this study was to evaluate serum levels of PSA, NSE, of angiogening factors (HER-2, ANG, VEGF-C, MMP2, MMP9, TIMP2, IGF1, IGFBP3) and bone metabolism markers (OPG, PINP, ICTP, CTx) in relation with PCa bone metastatic spread and to assess their expression during disease progression. A total of 204 males were included in the study: 131 patients with prostatic adenocarcinoma, 32 with benign prostatic hyperplasia and 45 healthy male controls. PCa patients were divided into two groups: with and without bone metastases (Κ2 and Κ1 group respectively).Our results support that bone markers PINP, ICTP, CTx and OPG are remarkably elevated in K2 group. Especially OPG shows a high sensitivity and specificity in detecting bone metastatic disease. So, serum bone marker measurement appears to be a promising method for monitoring the efficacy of bone-targeted therapy. In PCa elevated serum NSE values are related with poor prognosis. In our study, NSE levels were significantly higher in advanced metastatic PCa identifing a more aggressive disease, while they did not significantly differ among the other groups. Serum IGF1 and IGFBP-3 levels have been associated with increased risk and advanced stage of PCa. Our results do not support the case for IGF1 and IGFBP3 as potential biomarkers of prostate cancer behavior.ANG expression in prostatic tissue increases as prostatic epithelial cells evolve from a benign to an invasive type. Our results demonstrate that higher serum ANG levels were observed in metastatic patients and in disease progression, indicating that ANG could be a potential marker for monitoring PCa patients in clinical setting.HER-2/neu is an important mediator of cell growth, differentiation and survival. In this study, HER-2 was found to be overexpressed in serum of advanced metastatic prostate cancers revealing that the androgen receptor pathway functions despite anti-androgen therapy in androgen-independent tumors.Matrix metalloproteinases are devoted to the degradation of extracellular matrix. MMP-2 and MMP-9 have been linked to cell invasion and the process of bone metastasis, while TIMP-2 is their tissue inhibitor. Our results show that serum MMP-2, MMP-9 concentrations were higher in metastatic patients, while TIMP-2 was reduced in PCa patients but without significance.Expression of VEGF has been revealed in prostate cells of normal, benign, and malignant phenotypes. In our study, metastatic PCa patients had higher serum VEGF-C levels but without significant difference between controls and organ-confined PCa patients, implying that VEGF-C could not play a crucial role in PCa. Our results are promising and suggest that the above factors, if selected properly and in…

Subjects/Keywords: Καρκίνος; Προστάτης; Αγγειογένεση; Οστικός μεταβολισμός; Μεταστάσεις; Cancer; Prostate; Angiogenesis; Bone metabolism; Metastases

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Siampanopoulou, M. (2014). Η διερεύνηση των παραγόντων αύξησης και αγγειογένεσης σε ασθενείς με καρκίνο του προστάτη με ή χωρίς οστικές μεταστάσεις: συσχέτιση με καρκινικούς δείκτες και απεικονιστικά ευρήματα. (Thesis). Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ). Retrieved from http://hdl.handle.net/10442/hedi/36948

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Siampanopoulou, Maria. “Η διερεύνηση των παραγόντων αύξησης και αγγειογένεσης σε ασθενείς με καρκίνο του προστάτη με ή χωρίς οστικές μεταστάσεις: συσχέτιση με καρκινικούς δείκτες και απεικονιστικά ευρήματα.” 2014. Thesis, Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ). Accessed March 08, 2021. http://hdl.handle.net/10442/hedi/36948.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Siampanopoulou, Maria. “Η διερεύνηση των παραγόντων αύξησης και αγγειογένεσης σε ασθενείς με καρκίνο του προστάτη με ή χωρίς οστικές μεταστάσεις: συσχέτιση με καρκινικούς δείκτες και απεικονιστικά ευρήματα.” 2014. Web. 08 Mar 2021.

Vancouver:

Siampanopoulou M. Η διερεύνηση των παραγόντων αύξησης και αγγειογένεσης σε ασθενείς με καρκίνο του προστάτη με ή χωρίς οστικές μεταστάσεις: συσχέτιση με καρκινικούς δείκτες και απεικονιστικά ευρήματα. [Internet] [Thesis]. Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ); 2014. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/10442/hedi/36948.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Siampanopoulou M. Η διερεύνηση των παραγόντων αύξησης και αγγειογένεσης σε ασθενείς με καρκίνο του προστάτη με ή χωρίς οστικές μεταστάσεις: συσχέτιση με καρκινικούς δείκτες και απεικονιστικά ευρήματα. [Thesis]. Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ); 2014. Available from: http://hdl.handle.net/10442/hedi/36948

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

17. Barbezan, Angelica Bueno. Comparação da marcação de diversos fosfonatos: MDP, EDTMP e clodronato com 188Re.

Degree: Mestrado, Tecnologia Nuclear - Aplicações, 2012, University of São Paulo

URL: http://www.teses.usp.br/teses/disponiveis/85/85131/tde-16012013-091715/ ;

►

A grande aplicação dos radiofármacos está em medicina nuclear diagnóstica representando 95% dos procedimentos realizados, porém, nos últimos anos, tem crescido consideravelmente a sua aplicação… (more)

▼

A grande aplicação dos radiofármacos está em medicina nuclear diagnóstica representando 95% dos procedimentos realizados, porém, nos últimos anos, tem crescido consideravelmente a sua aplicação em procedimentos terapêuticos. Os radionuclídeos que emitem particulas ionizantes (α, β e elétrons Auger) são indicados para tratamento de tumores. Tumores malignos são responsáveis por aproximadamente 12% dos óbitos e representam a terceira causa de mortalidade no Brasil. O 188Re é um dos mais atrativos radioisótopos para uma variedade de aplicações terapêuticas em medicina nuclear, oncologia e intervenções cardiológicas, é totalmente favorável e conveniente pelo fato de que ele é livre de carregador e pode ser obtido de forma econômica na forma de um gerador de 188W/188Re, além de possuir uma meia-vida fisica de 16,9 horas e 100% de emissão de radiação β-. A partir da década de 2000 vêm sendo realizadas diversas investigações envolvendo marcações de moléculas com 188Re. Os tumores metastáticos são a forma mais comum de malignidade esquelética. Em casos metastáticos os principais objetivos do tratamento são a prevenção de fraturas patológicas e promover a sobrevida com o máximo de preservação de função permitindo que o paciente mantenha o máximo possível de mobilidade e controle da dor. O objetivo deste trabalho foi realizar a comparação das marcações de diversos fosfonatos (Metileno disfofonato de Sódio MDP, Ácido Etilenodiaminotetrametilenofosfônico EDTMP, e do diclorometilenobifosfonato de sódio - Clodronato) com 188Re para terapia de metastáses ósseas. Fosfonatos são inibidores da reabsorção óssea osteoclástica e são efetivos neste tratamento. As marcações do MDP, EDTMP e Clodronato com 188Re foram otimizadas utilizando como agente redutor o cloreto estanoso (SnCl2 2H2O) e como agente estabilizante o ácido ascórbico. As variáveis estudadas foram massa do ligante, massa do SnCl2.2H2O, massa do ácido ascórbico, tempo, pH e temperatura da reação. Os resultados mostraram que se obteve um excelente rendimento de marcação de 98% para o 188Re-MDP, de 83% para o 188Re-EDTMP e 85% para o 188Re-Clodronato.

The wide application of radiopharmaceuticals in nuclear medicine, representing 95% of procedures performed is in diagnosis, but in recent years, its application in therapeutic procedures has grown considerably. The radionuclides that emit ionizing particles (α, β, and Auger electrons) are indicated for the treatment of tumors. Malignant tumors account for approximately 12% of deaths and represent the third cause of mortality in Brazil. 188Re is one of the most attractive radioisotopes for a variety of therapeutic applications in nuclear medicine, oncology and cardiology interventions, is fully favorable and convenient because it is carrier free and can be obtained inexpensively in the form of a generator of 188W/188Re, and has a physical half-life of 16.9 hours and 100% of β-radiation emission. From the 2000s several investigations have been conducted involving molecules labeled with 188Re.…

Advisors/Committee Members: Osso Júnior, João Alberto.

Subjects/Keywords: 188Re; bifosfonato; biphosphonates; bone metastases therapy; bone pain; dor óssea; Rhenium-188; terapia de metástase óssea

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Barbezan, A. B. (2012). Comparação da marcação de diversos fosfonatos: MDP, EDTMP e clodronato com 188Re. (Masters Thesis). University of São Paulo. Retrieved from http://www.teses.usp.br/teses/disponiveis/85/85131/tde-16012013-091715/ ;

Chicago Manual of Style (16^th Edition):

Barbezan, Angelica Bueno. “Comparação da marcação de diversos fosfonatos: MDP, EDTMP e clodronato com 188Re.” 2012. Masters Thesis, University of São Paulo. Accessed March 08, 2021. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-16012013-091715/ ;.

MLA Handbook (7^th Edition):

Barbezan, Angelica Bueno. “Comparação da marcação de diversos fosfonatos: MDP, EDTMP e clodronato com 188Re.” 2012. Web. 08 Mar 2021.

Vancouver:

Barbezan AB. Comparação da marcação de diversos fosfonatos: MDP, EDTMP e clodronato com 188Re. [Internet] [Masters thesis]. University of São Paulo; 2012. [cited 2021 Mar 08]. Available from: http://www.teses.usp.br/teses/disponiveis/85/85131/tde-16012013-091715/ ;.

Council of Science Editors:

Barbezan AB. Comparação da marcação de diversos fosfonatos: MDP, EDTMP e clodronato com 188Re. [Masters Thesis]. University of São Paulo; 2012. Available from: http://www.teses.usp.br/teses/disponiveis/85/85131/tde-16012013-091715/ ;

18. Strazic, Ivana. Gallium, un candidat prometteur pour le traitement des pathologies osseuses : Gallium, a promising candidate for bone pathologies treatment.

Degree: Docteur es, Interactions moléculaires et cellulaires, 2015, Nice

URL: http://www.theses.fr/2015NICE4065

►

En chirurgie reconstructive osseuse les biomatériaux remplacent le tissu osseux manquant et dans le cas de pathologies ils peuvent également délivrer des molécules actives. L’élément… (more)

▼

En chirurgie reconstructive osseuse les biomatériaux remplacent le tissu osseux manquant et dans le cas de pathologies ils peuvent également délivrer des molécules actives. L’élément semi-métallique, gallium (Ga), est utilisé dans le traitement de différentes pathologies liées à la résorption accélérée de l’os dû à son effet inhibiteur sur les ostéoclastes (cellules résorbantes de l’os). Le Ga peut être incorporé dans la structure des biomatériaux osseux et nous nous sommes intéressés aux propriétés biologiques de ces derniers. In vitro, en présence de Ga nous avons mis en évidence une diminution de la différentiation des ostéoclastes, ainsi qu’une sur-expression de plusieurs marqueurs des ostéoblastes (cellules formatrices d’os). In vivo, le modèle murin de comblement du défaut osseux a montré une augmentation de la quantité de tissu osseux néoformé avec un biomatériau chargé en Ga vs. contrôle. Ces données démontrent que les biomatériaux chargés en Ga sont compatibles avec la survie et la prolifération des cellules osseuses et que le Ga peut améliorer la reconstruction osseuse. D’autre part, étant donné que des effets anti-tumoraux du Ga sont largement décrits, nous avons étudié ces effets sur une lignée cellulaire cancéreuse, choisie pour son affinité pour le tissu osseux. Nous avons montré que le Ga réduit la prolifération et probablement le potentiel tumoral de cette lignée, mais aussi la différentiation ostéoclastique induite par les cellules cancéreuses. Ces effets inhibiteurs observés dans un contexte tumoral indiquent que le Ga est un candidat intéressant pour le couplage avec des biomatériaux destinés au comblement osseux après une résection tumorale.

In bone reconstructive surgery biomaterials commonly replace the missing tissue and in case of pathologies can also serve as vectors for drug delivery. The semi-metallic element gallium (Ga) is used for the treatment of several disorders associated with accelerated bone resorption, due to its inhibitory action on bone-resorbing cells (osteoclasts). Since Ga can be incorporated into the structure of bone biomaterials, we embarked on characterising the biological properties of novel Ga-loaded materials. In vitro, we observed a decrease in osteoclast differentiation and the upregulated expression of several osteoblastic markers (bone-forming cells) in the presence of Ga-loaded biomaterial. In vivo, using a rat bone defect model, we showed an increase in newly formed bone tissue in implants filled with Ga-loaded biomaterial vs. control. Taken together, our data indicate that Ga-loaded biomaterials provide biocompatible substrates allowing bone cells survival and improved bone reconstruction in vivo. Taking into account antitumoral effects of Ga, largely described in literature, we also investigated its impact on a bone metastatic model. Using an aggressive human cancer cell line selected for its ability to invade bone tissue, we showed that Ga could reduce cancer cell proliferation and viability and reverse excessive osteoclastogenesis in bone metastatic…

Advisors/Committee Members: Scimeca, Jean-Claude (thesis director), Verron, Élise (thesis director).

Subjects/Keywords: Ostéoporose; Métastases osseuses; Gallium; Biomatériaux; Ingénierie tissulaire de l'os; Osteoporosis; Bone metastases; Gallium; Biomaterials; Bone tissue engineering

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Strazic, I. (2015). Gallium, un candidat prometteur pour le traitement des pathologies osseuses : Gallium, a promising candidate for bone pathologies treatment. (Doctoral Dissertation). Nice. Retrieved from http://www.theses.fr/2015NICE4065

Chicago Manual of Style (16^th Edition):

Strazic, Ivana. “Gallium, un candidat prometteur pour le traitement des pathologies osseuses : Gallium, a promising candidate for bone pathologies treatment.” 2015. Doctoral Dissertation, Nice. Accessed March 08, 2021. http://www.theses.fr/2015NICE4065.

MLA Handbook (7^th Edition):

Strazic, Ivana. “Gallium, un candidat prometteur pour le traitement des pathologies osseuses : Gallium, a promising candidate for bone pathologies treatment.” 2015. Web. 08 Mar 2021.

Vancouver:

Strazic I. Gallium, un candidat prometteur pour le traitement des pathologies osseuses : Gallium, a promising candidate for bone pathologies treatment. [Internet] [Doctoral dissertation]. Nice; 2015. [cited 2021 Mar 08]. Available from: http://www.theses.fr/2015NICE4065.

Council of Science Editors:

Strazic I. Gallium, un candidat prometteur pour le traitement des pathologies osseuses : Gallium, a promising candidate for bone pathologies treatment. [Doctoral Dissertation]. Nice; 2015. Available from: http://www.theses.fr/2015NICE4065

19. Mavriopoulou, Eleni. Η συνεισφορά της μεθόδου SPECT/CT στην ανάδειξη δευτεροπαθών εντοπίσεων στα οστά ασθενών με καρκίνο του μαστού.

Degree: 2018, University of Patras; Πανεπιστήμιο Πατρών

URL: http://hdl.handle.net/10442/hedi/45274

►

Objective: Single photon emission tomography/computed tomography (SPET/CT) is usually recommended after ambiguous whole body bone scan (WBS) findings. We investigated the value of routine 2-field… (more)

▼

Objective: Single photon emission tomography/computed tomography (SPET/CT) is usually recommended after ambiguous whole body bone scan (WBS) findings. We investigated the value of routine 2-field (“near” whole-body) SPET/CT application in breast cancer (BC) patients. Subjects and Methods: In this prospective study planar WBS and 2-field SPET/CT was performed in 257 consecutive BC patients referred for a bone scan. Whole body scan and SPET/CT were interpreted separately. Additional imaging studies and clinical follow-up for 30±24 months elucidated uncertain findings. Results: Bone metastases were confirmed in 65 patients (25.3%). Sensitivity, specificity, accuracy, positive and negative predictive value per-patient was 63.1%, 81.3%, 76.7%, 53.2% and 86.7% for WBS and 96.9%, 87.5%, 89.9%, 72.4% and 98,8% for SPET/CT; differences were statistically significant except for specificity. Respective values of sensitivity per-lesion were 47.6% and 98.9% (P<0.001). Eleven percent of true positive findings were noticed only in the low-dose CT images, while 7% only in SPET. Single photon emission tomography/CT exhibited higher specificity than WBS in the spine (94.8% vs. 88.7%, P=0.04). Whole body scan interpretation changed after SPET/CT in 74 (28.8%) patients. Thirty-two patients with positive/suspicious WBS turned to be metastases-free after the interpretation of SPET/CT while 42 with unremarkable WBS turned to be positive/suspicious. Of these cases, metastases were confirmed in one with negative and 23 with positive/suspicious SPET/CT. The SPET/CT results prompted treatment plan changes in 23 cases (8.9%). Conclusions: Whole-body bone SPET/CT scan outperformed WBS in terms of sensitivity, accuracy, positive and negative predictive value and impacted on patient management. Therefore, its use is recommended as a routine procedure in BC patients, even after a negative WBS.

Σκοπός: Η τομογραφία εκπομπής μονήρους φωτονίου σε συνδυασμό με αξονική τομογραφία (SPECT/CT) συνιστάται σαν συμπληρωματική μέθοδος σε περιπτώσεις ολόσωμου στατικού σπινθηρογραφήματος οστών με ασαφή ή ύποπτα ευρήματα προκειμένου να διενεργηθεί περαιτέρω διερεύνηση αυτών των ευρημάτων. Στην παρούσα μελέτη ερευνήθηκε η πρόσθετη αξία της διενέργειας σχεδον ολόσωμης τομογραφικής SPECT/CT απεικόνισης 2 πεδίων σε ασθενείς με καρκίνο του μαστου σαν εξέταση ρουτίνας μαζί με το στατικό σπινθηρογραφήμα ανεξαρτήτως των ευρημάτων.Υλικά και μέθοδοι: Σε αυτήν την προοπτική μελέτη στρατολογήθηκαν 257 ασθενείς με καρκίνο του μαστού, οι οποιοι υποβλήθηκαν σε ολοσωμο σπινθηρογράφημα οστών και ακολούθως σε τομογραφική SPECT/CT απεικόνιση 2 πεδίων. Η στατική και η τομογραφική μελέτη ερμηνεύθηκαν ξεχωριστά. Ενδεχόμενα ασαφή ευρήματα αποσαφηνίστηκαν μετά την διενέργεία πρόσθετων απεικονιστικών εξετάσεων καθώς και παρακολούθησης των ασθενών για διάστημα 30±24 μήνες.Αποτελέσματα: Οστικές μεταστάσεις επιβεβαιώθηκαν σε 65 ασθενείς (25,3%). Η ευαισθησία, η ειδικότητα, η ακρίβεια και η θετική και αρνητική προγνωστική αξία στην ανάλυση σε επίπεδο ασθενών ήταν 63,1%, 81,3%, 76,7%,…

Subjects/Keywords: Σπινθηρογράφημα οστών; Τομογραφία εκπομπής μονήρους φωτονίου; Μεταστάσεις οστών; Καρκίνος μαστού; Bone scan; Single photon emission tomography; Bone metastases; Breast cancer

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Mavriopoulou, E. (2018). Η συνεισφορά της μεθόδου SPECT/CT στην ανάδειξη δευτεροπαθών εντοπίσεων στα οστά ασθενών με καρκίνο του μαστού. (Thesis). University of Patras; Πανεπιστήμιο Πατρών. Retrieved from http://hdl.handle.net/10442/hedi/45274

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Mavriopoulou, Eleni. “Η συνεισφορά της μεθόδου SPECT/CT στην ανάδειξη δευτεροπαθών εντοπίσεων στα οστά ασθενών με καρκίνο του μαστού.” 2018. Thesis, University of Patras; Πανεπιστήμιο Πατρών. Accessed March 08, 2021. http://hdl.handle.net/10442/hedi/45274.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Mavriopoulou, Eleni. “Η συνεισφορά της μεθόδου SPECT/CT στην ανάδειξη δευτεροπαθών εντοπίσεων στα οστά ασθενών με καρκίνο του μαστού.” 2018. Web. 08 Mar 2021.

Vancouver:

Mavriopoulou E. Η συνεισφορά της μεθόδου SPECT/CT στην ανάδειξη δευτεροπαθών εντοπίσεων στα οστά ασθενών με καρκίνο του μαστού. [Internet] [Thesis]. University of Patras; Πανεπιστήμιο Πατρών; 2018. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/10442/hedi/45274.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Mavriopoulou E. Η συνεισφορά της μεθόδου SPECT/CT στην ανάδειξη δευτεροπαθών εντοπίσεων στα οστά ασθενών με καρκίνο του μαστού. [Thesis]. University of Patras; Πανεπιστήμιο Πατρών; 2018. Available from: http://hdl.handle.net/10442/hedi/45274

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Gothenburg / Göteborgs Universitet

20. Kaboteh, Reza. Quantitative analysis of bone scans in prostate cancer patients.

Degree: 2013, University of Gothenburg / Göteborgs Universitet

URL: http://hdl.handle.net/2077/33119

► Prostate cancer (PCa) is one of the most common diseases in the world. PCa can primarily disseminate to the bone, causing bone metastases, which in… (more)

▼ Prostate cancer (PCa) is one of the most common diseases in the world. PCa can primarily disseminate to the bone, causing bone metastases, which in turn can lead to death. It is important to diagnose bone metastases as soon as possible in order to treat the disease. Bone metastases are diagnosed commonly by bone scan imaging. However, interpretation of bone scan images is not always an easy task for physicians. One way of minimising the risk of misinterpretation is quantitative analysis of bone scan images in order to ascertain whether they show any metastatic lesions, and if so, to what extent. Quantification of the bone scan, i.e. the bone scan index (BSI) method, could be used for prognostication of survival, or to follow up the effect of treatment. The aim of the thesis was to develop and validate a fully automated method for the quantification of skeletal images in patients with prostate cancer based on the BSI method. This thesis is based on four papers. In paper 1, "A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index", we developed an automated BSI-quantification method, used it in a training group of 795 patients, compared it to a manual method and assessed the prognostic value of BSI in an evaluating group of 384 patients. The automated method showed a good correlation (r=80%) with the manual method, and BSI was strongly associated with prostate cancer death. In paper 2, "Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy”, we found that BSI included prognostic information in addition to other clinical parameters such as “prostate-specific antigens”. Patients with BSI<1 had a much higher survival rate after 5 years than those with BSI>5. In paper 3, “Progression of Bone Metastases in Patients with Prostate Cancer - Automated Detection of New Lesions and Calculation of Bone Scan Index”, we further develop the automatic method to find new metastases using a training group of 266 patients. The method evaluated 31 patients who received chemotherapy. Patients with an increase in BSI during treatment had a lower two-year survival rate (18%) than those with a decrease in BSI (57%). In the final paper, “Assessment of baseline and longitudinal bone scan index measures in the context of a randomised placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)”, we retrospectively calculated BSI at baseline and upon treatment in 85 patients from a clinical trial. We found that BSI and BSI change on-treatment were associated with survival. BSI correlated with known biomarkers of survival, but adds independent prognostic information. In conclusion, BSI calculated using an automated method contains prognostic information and can be used to evaluate treatment effects.

Subjects/Keywords: Image analysis; Radionuclide imaging; Bone metastases; Prostate cancer; Automated detection; Bone scan index; Computer assisted diagnosis

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Kaboteh, R. (2013). Quantitative analysis of bone scans in prostate cancer patients. (Thesis). University of Gothenburg / Göteborgs Universitet. Retrieved from http://hdl.handle.net/2077/33119

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Kaboteh, Reza. “Quantitative analysis of bone scans in prostate cancer patients.” 2013. Thesis, University of Gothenburg / Göteborgs Universitet. Accessed March 08, 2021. http://hdl.handle.net/2077/33119.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Kaboteh, Reza. “Quantitative analysis of bone scans in prostate cancer patients.” 2013. Web. 08 Mar 2021.

Vancouver:

Kaboteh R. Quantitative analysis of bone scans in prostate cancer patients. [Internet] [Thesis]. University of Gothenburg / Göteborgs Universitet; 2013. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/2077/33119.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Kaboteh R. Quantitative analysis of bone scans in prostate cancer patients. [Thesis]. University of Gothenburg / Göteborgs Universitet; 2013. Available from: http://hdl.handle.net/2077/33119

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Universidade Federal de Santa Maria

21. Maria Elisa Trost. NEOPLASMAS ÓSSEOS E OSTEOPATIA HIPERTRÓFICA EM CÃES.

Degree: 2013, Universidade Federal de Santa Maria

URL: http://coralx.ufsm.br/tede/tde_busca/arquivo.php?codArquivo=5084

► This doctoral thesis involved the study of three groups of neoplasms that affect bones of dogs (primary bone neoplasms, bone metastases, and multicentric neoplasms with… (more)

Subjects/Keywords: doenças de cães; patologia óssea; osteopatia hipertrófica; metástases ósseas; neoplasmas ósseos primários; MEDICINA VETERINARIA; primary bone neoplasms; bone metastases; hypertrophic osteopathy; bone pathology; diseases of dogs

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Trost, M. E. (2013). NEOPLASMAS ÓSSEOS E OSTEOPATIA HIPERTRÓFICA EM CÃES. (Thesis). Universidade Federal de Santa Maria. Retrieved from http://coralx.ufsm.br/tede/tde_busca/arquivo.php?codArquivo=5084

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Trost, Maria Elisa. “NEOPLASMAS ÓSSEOS E OSTEOPATIA HIPERTRÓFICA EM CÃES.” 2013. Thesis, Universidade Federal de Santa Maria. Accessed March 08, 2021. http://coralx.ufsm.br/tede/tde_busca/arquivo.php?codArquivo=5084.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Trost, Maria Elisa. “NEOPLASMAS ÓSSEOS E OSTEOPATIA HIPERTRÓFICA EM CÃES.” 2013. Web. 08 Mar 2021.

Vancouver:

Trost ME. NEOPLASMAS ÓSSEOS E OSTEOPATIA HIPERTRÓFICA EM CÃES. [Internet] [Thesis]. Universidade Federal de Santa Maria; 2013. [cited 2021 Mar 08]. Available from: http://coralx.ufsm.br/tede/tde_busca/arquivo.php?codArquivo=5084.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Trost ME. NEOPLASMAS ÓSSEOS E OSTEOPATIA HIPERTRÓFICA EM CÃES. [Thesis]. Universidade Federal de Santa Maria; 2013. Available from: http://coralx.ufsm.br/tede/tde_busca/arquivo.php?codArquivo=5084

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

22. Le Pape, François. ROBO4 dans les cellules métastatiques du cancer du sein : identification et caractérisation fonctionnelle d’isoformes protéiques : ROBO4 in metastatic breast cancer cells : identification and functional characterization of protein isoforms.

Degree: Docteur es, Cancérologie, 2017, Lyon

URL: http://www.theses.fr/2017LYSE1269

►

Les métastases osseuses sont des complications fréquentes de nombreux cancers tels que le cancer du poumon, de la prostate et du sein. Chez la femme,… (more)

▼

Les métastases osseuses sont des complications fréquentes de nombreux cancers tels que le cancer du poumon, de la prostate et du sein. Chez la femme, 70% des patientes présentant un cancer du sein avancé développent des métastases qualifiées d’ostéolytiques. Le développement de ce type de métastases entraine la destruction massive de l’os causant chez les patientes des fractures pathologiques. Les traitements actuellement dispensés en clinique tels que les bisphosphonates et le dénosumab (anti-RANKL) ne sont pas curatifs mais seulement palliatifs. Pour cette raison, notre laboratoire s’intéresse particulièrement aux évènements moléculaires et cellulaires précoces aboutissant à l’émergence de métastases osseuses. Les récepteurs Roundabout (ROBO) ont été initialement décrits comme des régulateurs cruciaux de la migration neuronale et vasculaire lors du développement. ROBO4 est le dernier récepteur décrit et diverge des autres récepteurs ROBO, notamment par son expression spécifique et limitée aux cellules endothéliales et hématopoïétiques. Toutefois, lors d’une analyse transcriptomique comparative le récepteur ROBO4 a été retrouvé surexprimé dans la lignée tumorale ostéotropique MDA-B02. Les récentes expériences, réalisées par notre équipe, visant à inhiber l’activité du récepteur ROBO4, nous ont permis de considérer le récepteur ROBO4 comme un médiateur de l’ancrage à l’os des cellules tumorales MDA-B02. En effet, L’utilisation d’un anticorps anti-ROBO4 réduit considérablement l'adhérence des cellules MDA-B02 sur les cellules ostéoblastiques MC3T3-E1 in vitro et l’ancrage à l’os in vivo. La surexpression de ROBO4 dans un modèle cellulaire de cancer du sein murin nous a conduit à mettre en évidence la présence de deux formes de la protéine ROBO4 aux propriétés antagonistes : (i) une forme glycosylée détectée exclusivement dans les cellules endothéliales et (ii) une forme non glycosylée, issue d’un transcrit alternatif et présente en forte quantité dans les cellules tumorales MDA-B02. L’identification d’un variant protéique du récepteur ROBO4 aux propriétés fonctionnelles et structurales différentes nous a permis d’envisager de nouvelles pistes dans le décryptage des fonctions de ROBO4 dans le processus tumoral et pourrait conduire à la mise au point de thérapies innovantes pour empêcher la formation de métastases dans la moelle osseuse

Bone metastases are frequent complications of many cancers such as lung, prostate and breast cancer. In women, 70% of patients with advanced breast cancer develop metastases known as osteolytic. The development of this type of metastasis leads to the mass destruction of bone causing pathological fractures in patients. Current clinical treatments such as bisphosphonates and denosumab (anti-RANKL) only slow the progression of the disease. For this reason, our laboratory is particularly interested in early molecular and cellular events leading to the emergence of bone metastases. Roundabout receptors (ROBO) were initially described as crucial regulators of neuronal and vascular migration…

Advisors/Committee Members: Latoud, Chantal (thesis director).

Subjects/Keywords: ROBO4; Métastases osseuses; Cancer du sein; Glycosylation; Transcrits alternatifs; ROBO4; Bone metastases; Breast cancer; Glycosylation; Alternative Transcripts; 616.99

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Le Pape, F. (2017). ROBO4 dans les cellules métastatiques du cancer du sein : identification et caractérisation fonctionnelle d’isoformes protéiques : ROBO4 in metastatic breast cancer cells : identification and functional characterization of protein isoforms. (Doctoral Dissertation). Lyon. Retrieved from http://www.theses.fr/2017LYSE1269

Chicago Manual of Style (16^th Edition):

Le Pape, François. “ROBO4 dans les cellules métastatiques du cancer du sein : identification et caractérisation fonctionnelle d’isoformes protéiques : ROBO4 in metastatic breast cancer cells : identification and functional characterization of protein isoforms.” 2017. Doctoral Dissertation, Lyon. Accessed March 08, 2021. http://www.theses.fr/2017LYSE1269.

MLA Handbook (7^th Edition):

Le Pape, François. “ROBO4 dans les cellules métastatiques du cancer du sein : identification et caractérisation fonctionnelle d’isoformes protéiques : ROBO4 in metastatic breast cancer cells : identification and functional characterization of protein isoforms.” 2017. Web. 08 Mar 2021.

Vancouver:

Le Pape F. ROBO4 dans les cellules métastatiques du cancer du sein : identification et caractérisation fonctionnelle d’isoformes protéiques : ROBO4 in metastatic breast cancer cells : identification and functional characterization of protein isoforms. [Internet] [Doctoral dissertation]. Lyon; 2017. [cited 2021 Mar 08]. Available from: http://www.theses.fr/2017LYSE1269.

Council of Science Editors:

Le Pape F. ROBO4 dans les cellules métastatiques du cancer du sein : identification et caractérisation fonctionnelle d’isoformes protéiques : ROBO4 in metastatic breast cancer cells : identification and functional characterization of protein isoforms. [Doctoral Dissertation]. Lyon; 2017. Available from: http://www.theses.fr/2017LYSE1269

Vanderbilt University

23. Johnson, Lindsay Craig. Imaging of Osteolytic Breast Cancer Metastases with Computed Tomography, Positron Emission Tomography and Single Photon Emission Computed Tomography.

Degree: MS, Biomedical Engineering, 2010, Vanderbilt University

URL: http://hdl.handle.net/1803/11760

► Imaging protocols for detection of breast cancer metastases to bone in clinical imaging have long been standardized, but to date small animal imaging still uses… (more)

Subjects/Keywords: PET; imaging; bone metastases; breast cancer; SPECT; CT

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Johnson, L. C. (2010). Imaging of Osteolytic Breast Cancer Metastases with Computed Tomography, Positron Emission Tomography and Single Photon Emission Computed Tomography. (Thesis). Vanderbilt University. Retrieved from http://hdl.handle.net/1803/11760

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Johnson, Lindsay Craig. “Imaging of Osteolytic Breast Cancer Metastases with Computed Tomography, Positron Emission Tomography and Single Photon Emission Computed Tomography.” 2010. Thesis, Vanderbilt University. Accessed March 08, 2021. http://hdl.handle.net/1803/11760.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Johnson, Lindsay Craig. “Imaging of Osteolytic Breast Cancer Metastases with Computed Tomography, Positron Emission Tomography and Single Photon Emission Computed Tomography.” 2010. Web. 08 Mar 2021.

Vancouver:

Johnson LC. Imaging of Osteolytic Breast Cancer Metastases with Computed Tomography, Positron Emission Tomography and Single Photon Emission Computed Tomography. [Internet] [Thesis]. Vanderbilt University; 2010. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/1803/11760.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Johnson LC. Imaging of Osteolytic Breast Cancer Metastases with Computed Tomography, Positron Emission Tomography and Single Photon Emission Computed Tomography. [Thesis]. Vanderbilt University; 2010. Available from: http://hdl.handle.net/1803/11760

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

24. 時任, 高章. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases : 骨転移を有する非扁平上皮非小細胞肺癌に対するベバシズマブ併用化学療法の有用性.

Degree: 博士（医学）, 2018, Kurume University / 久留米大学

URL: http://hdl.handle.net/11316/308

2014年度

Subjects/Keywords: Bone metastases; Skeletal-related event; Bevacizumab; Chemotherapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

時任, �. (2018). Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases : 骨転移を有する非扁平上皮非小細胞肺癌に対するベバシズマブ併用化学療法の有用性. (Thesis). Kurume University / 久留米大学. Retrieved from http://hdl.handle.net/11316/308

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

時任, 高章. “Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases : 骨転移を有する非扁平上皮非小細胞肺癌に対するベバシズマブ併用化学療法の有用性.” 2018. Thesis, Kurume University / 久留米大学. Accessed March 08, 2021. http://hdl.handle.net/11316/308.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

時任, 高章. “Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases : 骨転移を有する非扁平上皮非小細胞肺癌に対するベバシズマブ併用化学療法の有用性.” 2018. Web. 08 Mar 2021.

Vancouver:

時任 �. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases : 骨転移を有する非扁平上皮非小細胞肺癌に対するベバシズマブ併用化学療法の有用性. [Internet] [Thesis]. Kurume University / 久留米大学; 2018. [cited 2021 Mar 08]. Available from: http://hdl.handle.net/11316/308.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

時任 �. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases : 骨転移を有する非扁平上皮非小細胞肺癌に対するベバシズマブ併用化学療法の有用性. [Thesis]. Kurume University / 久留米大学; 2018. Available from: http://hdl.handle.net/11316/308

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

25. Dancheva, Zhivka / Данчева, Живка. Metabolic Radiopharmaceutical Therapy with 89-Sr (Metastron) for Metastatic Bone Pain // Метаболитна радиофармацевтична терапия със 89-Sr (Metastron) при болезнени костни метастази.

Degree: 2012, Medical University of Varna

URL: http://repository.mu-varna.bg/handle/nls/159

► [EN] Bone Metastasis Pain is a major therapeutic problem, influencing physical, physiological health and the quality of life. The first radionuclide used for bone pain… (more)

▼ [EN] Bone Metastasis Pain is a major therapeutic problem, influencing physical, physiological health and the quality of life. The first radionuclide used for bone pain is 32-P. Nowadays, radiopharmaceutical therapy of bone cancer pain is conducted with several radiopharmeceuticals 89-Sr, 153-Sm, 186 Re. 89-Sr is a beta -emitter, with a half-life of 50.6 days and maximum range in bone tissue 3.5mm. There are some unresolved issues about its application outlined as future investigation issues in the guidelines of the European Association of Nuclear Medicine and the American Society of Nuclear medicine. The evaluation of chronic pain is difficult because of its holistic character, concerning not only the sensation of pain, but its physical impairment, emotional, psychological, economic, social and spiritual component. In this work we evaluate not only the therapy effect on the performance status, but on radiological studies as well, and define its influence on the time of progression of bone metastatic disease. There are insufficient number of studies about the synergistic effect of 89-Sr with conventional therapy such as bisphosphonates, chemotherapy and local radiotherapy. There are a small number of indication parameters consisting mainly of osteoblastic metastases and radiologically and scintigraphically proved bone metastases. In our study, we evaluated the role of pretherapeutic patient characteristics on the pain control after 89-Sr application, such as pretherapeutic performance status, additional observation on patients with mixed and osteolytic metastases, the extend of bone metastatic disease (oligometastases or multiple metastases), the presence of visceral metastases, except bone involvement. Furthermore we evaluate the pain flair phenomena, toxic effects and the role of further therapies. We summarize all data received in structured criteria for optimized selection of patients for therapy with 89-Sr. /////// /////// [BG] Метастатичната костна болест (МКБ) съпътства прогресията на множество различни злокачествени заболявания, но най-често се наблюдава при карцином на простатата, на гърдата и белия дроб. Контролът на раковата представлява голям проблем. Тя е хронична по характер и подобно на немалигнената хронична болка, тя е свързана с ограничение на пърформанс статуса (ПС) и психологичен дистрес. Използването на метаболитна радиофармацевтична терапия за лечение на болезнени костни метастази е било използвано изключително за палиативна терапия. Важно предимство на 89-Sr е възможността да се комбинира с медикаменти, прилагани за контрол на онкологичното заболяване - химиотерапия, лъчелечение, ендокринна и таргетна терапия. От направения анализ на литературата, остава открит въпросът за ползите от комбинираното лечение на 89-Sr с бифосфонат, химиотерапия или лъчелечение, по отношение на ПС, радиологичния отговор на костните метастази и времето до прогресия. Проведени са само три малки рандомизирани контролирани проучвания. В препоръките на EANM и SNM, като задача за бъдещи проучвания е заложено проучване на…

Subjects/Keywords: metastatic bone pain; metastases; therapy; Metastron; radiopharmaceutical; radiological; Образна диагностика и лъчелечение / Diagnostic Imaging and Radiotherapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Dancheva, Zhivka / Данчева, �. (2012). Metabolic Radiopharmaceutical Therapy with 89-Sr (Metastron) for Metastatic Bone Pain // Метаболитна радиофармацевтична терапия със 89-Sr (Metastron) при болезнени костни метастази. (Thesis). Medical University of Varna. Retrieved from http://repository.mu-varna.bg/handle/nls/159

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Dancheva, Zhivka / Данчева, Живка. “Metabolic Radiopharmaceutical Therapy with 89-Sr (Metastron) for Metastatic Bone Pain // Метаболитна радиофармацевтична терапия със 89-Sr (Metastron) при болезнени костни метастази.” 2012. Thesis, Medical University of Varna. Accessed March 08, 2021. http://repository.mu-varna.bg/handle/nls/159.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Dancheva, Zhivka / Данчева, Живка. “Metabolic Radiopharmaceutical Therapy with 89-Sr (Metastron) for Metastatic Bone Pain // Метаболитна радиофармацевтична терапия със 89-Sr (Metastron) при болезнени костни метастази.” 2012. Web. 08 Mar 2021.

Vancouver:

Dancheva, Zhivka / Данчева �. Metabolic Radiopharmaceutical Therapy with 89-Sr (Metastron) for Metastatic Bone Pain // Метаболитна радиофармацевтична терапия със 89-Sr (Metastron) при болезнени костни метастази. [Internet] [Thesis]. Medical University of Varna; 2012. [cited 2021 Mar 08]. Available from: http://repository.mu-varna.bg/handle/nls/159.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Dancheva, Zhivka / Данчева �. Metabolic Radiopharmaceutical Therapy with 89-Sr (Metastron) for Metastatic Bone Pain // Метаболитна радиофармацевтична терапия със 89-Sr (Metastron) при болезнени костни метастази. [Thesis]. Medical University of Varna; 2012. Available from: http://repository.mu-varna.bg/handle/nls/159

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Texas Medical Center

26. Xu, Jia. 14-3-3 ZETA OVEREXPRESSION SERVES AS A NOVEL MOLECULAR SWITCH TURNING TGF-BETA FROM TUMOR SUPPRESSOR TO TUMOR PROMOTER.

Degree: PhD, 2012, Texas Medical Center

URL: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/268

► TGF-β plays an important role in differentiation and tissue morphogenesis as well as cancer progression. However, the role of TGF-β in cancer is complicate.… (more)

Subjects/Keywords: 14-3-3 zeta; TGF-beta; molecular switch; 14-3-3 sigma; breast cancer; bone metastases; Gli2; p53; YAP1; Cancer Biology

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Xu, J. (2012). 14-3-3 ZETA OVEREXPRESSION SERVES AS A NOVEL MOLECULAR SWITCH TURNING TGF-BETA FROM TUMOR SUPPRESSOR TO TUMOR PROMOTER. (Doctoral Dissertation). Texas Medical Center. Retrieved from https://digitalcommons.library.tmc.edu/utgsbs_dissertations/268

Chicago Manual of Style (16^th Edition):

Xu, Jia. “14-3-3 ZETA OVEREXPRESSION SERVES AS A NOVEL MOLECULAR SWITCH TURNING TGF-BETA FROM TUMOR SUPPRESSOR TO TUMOR PROMOTER.” 2012. Doctoral Dissertation, Texas Medical Center. Accessed March 08, 2021. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/268.

MLA Handbook (7^th Edition):

Xu, Jia. “14-3-3 ZETA OVEREXPRESSION SERVES AS A NOVEL MOLECULAR SWITCH TURNING TGF-BETA FROM TUMOR SUPPRESSOR TO TUMOR PROMOTER.” 2012. Web. 08 Mar 2021.

Vancouver:

Xu J. 14-3-3 ZETA OVEREXPRESSION SERVES AS A NOVEL MOLECULAR SWITCH TURNING TGF-BETA FROM TUMOR SUPPRESSOR TO TUMOR PROMOTER. [Internet] [Doctoral dissertation]. Texas Medical Center; 2012. [cited 2021 Mar 08]. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/268.

Council of Science Editors:

Xu J. 14-3-3 ZETA OVEREXPRESSION SERVES AS A NOVEL MOLECULAR SWITCH TURNING TGF-BETA FROM TUMOR SUPPRESSOR TO TUMOR PROMOTER. [Doctoral Dissertation]. Texas Medical Center; 2012. Available from: https://digitalcommons.library.tmc.edu/utgsbs_dissertations/268

27. Fradet, Anaïs. Rôle du récepteur nucléaire orphelin ERRalpha dans le développement des métastases osseuses du cancer du sein et de la prostate : Role of the orphan nuclear receptor ERRalpha in the development of breast cancer and prostate cancer bone metastases.

Degree: Docteur es, Sciences de la Vie et de la Santé, 2012, Université Claude Bernard – Lyon I

URL: http://www.theses.fr/2012LYO10308

►

Chez les patients atteints d’un cancer du sein ou de la prostate, le tissu osseux est souvent le siège de métastases qui présentent un phénotype… (more)

▼

Chez les patients atteints d’un cancer du sein ou de la prostate, le tissu osseux est souvent le siège de métastases qui présentent un phénotype essentiellement lytique dans le cas des métastases dérivant du cancer du sein, ou mixte (combinaison de lyse et de formation osseuse) dans le cas d’un cancer de la prostate. Le récepteur ERRalpha est impliqué dans la physiologie osseuse et il est considéré comme un facteur de mauvais pronostic dans ces deux types de cancers. Nous avons donc émis l’hypothèse qu'il pourrait être impliqué dans la formation des métastases osseuses associées à ces deux cancers. Nous avons observé que, dans les deux cas, ERRalpha stimule la progression tumorale au site primaire via la stimulation de l'angiogenèse et de l'expression du VEGF. Concernant les métastases osseuses dérivant du cancer du sein, ERRalpha inhibe les lésions ostéolytiques via la modulation de l'ostéoclastogenèse et de l'expression de son inhibiteur, l’OPG. A l'inverse, l'expression de ERRalpha stimule la formation de lésions lytiques induites par les cellules de cancer de la prostate en induisant l'expression du TGF-beta, de MCP-1 et de la cathépsine K, tout en induisant des zones de formation osseuse via la régulation de l'expression de l'OPG, de l’endothéline-1 et de membres de la famille Wnt. Ces résultats confirment la valeur de facteur de mauvais pronostic de ERRalpha dans la tumeur primaire. De plus, ils révèlent, pour la première fois, son implication dans le développement des métastases osseuses et suggèrent une dualité fonctionnelle de ERRalpha, comme inhibiteur et stimulateur du développement des métastases osseuses du cancer du sein et de la prostate, respectivement. Ces résultats suggèrent des mécanismes d'action différents pouvant dépendre des cellules tumorales mais aussi du microenvironnement et du statut hormonal

Breast cancer and prostate cancer patients, often developed bone metastases. As ERRalpha, an orphan nuclear receptor, is involved in bone physiology and is considered as a bad prognosis factor in breast and prostate cancer, we hypothesize that it can be implicated in bone metastasis development that derived from breast and prostate cancers. While we found that, in both cases, ERRalpha stimulates the development of the primary tumor through regulation of angiogenesis and VEGF expression, we show that ERRalpha inhibits osteolytic lesions from breast cancer cells via the regulation of osteoclastogenesis and OPG expression. On the other side ERRalpha stimulates osteolytic lesions from prostate cancer through regulation of TGFbeta, MCP-1 and cathepsin K expression while inducing new bone formation combine with OPG, endothelin-1, and Wnts regulation. All together, our results confirmed ERRalpha as a bad prognosis factor in breast and prostate primary tumors. They also show a dual function of ERRalpha in bone metastasis development as an inhibitor and a stimulator of bone metastasis derived from breast and prostate cancer respectively which suggest different ERRalpha mechanisms that may depend of cancer…

Advisors/Committee Members: Clezardin, Philippe (thesis director), Bonnelye, Edith (thesis director).

Subjects/Keywords: ERRalpha; Métastases osseuses; Cancer de la prostate; Cancer du sein; ERRalpha; Bone metastases; Prostate cancer; Breast cancer; 616.99

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Fradet, A. (2012). Rôle du récepteur nucléaire orphelin ERRalpha dans le développement des métastases osseuses du cancer du sein et de la prostate : Role of the orphan nuclear receptor ERRalpha in the development of breast cancer and prostate cancer bone metastases. (Doctoral Dissertation). Université Claude Bernard – Lyon I. Retrieved from http://www.theses.fr/2012LYO10308

Chicago Manual of Style (16^th Edition):

Fradet, Anaïs. “Rôle du récepteur nucléaire orphelin ERRalpha dans le développement des métastases osseuses du cancer du sein et de la prostate : Role of the orphan nuclear receptor ERRalpha in the development of breast cancer and prostate cancer bone metastases.” 2012. Doctoral Dissertation, Université Claude Bernard – Lyon I. Accessed March 08, 2021. http://www.theses.fr/2012LYO10308.

MLA Handbook (7^th Edition):

Fradet, Anaïs. “Rôle du récepteur nucléaire orphelin ERRalpha dans le développement des métastases osseuses du cancer du sein et de la prostate : Role of the orphan nuclear receptor ERRalpha in the development of breast cancer and prostate cancer bone metastases.” 2012. Web. 08 Mar 2021.

Vancouver:

Fradet A. Rôle du récepteur nucléaire orphelin ERRalpha dans le développement des métastases osseuses du cancer du sein et de la prostate : Role of the orphan nuclear receptor ERRalpha in the development of breast cancer and prostate cancer bone metastases. [Internet] [Doctoral dissertation]. Université Claude Bernard – Lyon I; 2012. [cited 2021 Mar 08]. Available from: http://www.theses.fr/2012LYO10308.

Council of Science Editors:

Fradet A. Rôle du récepteur nucléaire orphelin ERRalpha dans le développement des métastases osseuses du cancer du sein et de la prostate : Role of the orphan nuclear receptor ERRalpha in the development of breast cancer and prostate cancer bone metastases. [Doctoral Dissertation]. Université Claude Bernard – Lyon I; 2012. Available from: http://www.theses.fr/2012LYO10308

28. Tardoski, Sophie. Traitement des métastases osseuses par association d’un bisphosphonate avec des ultrasons de faible intensité : Treatment of bone metastases with a bisphosphonate and low intensity ultrasound.

Degree: Docteur es, Sciences biologiques, 2015, Université Claude Bernard – Lyon I

URL: http://www.theses.fr/2015LYO10162

►

Les métastases osseuses sont une complication majeure des cancers du sein. Les bisphosphonates (BPs) bloquent la progression des lyses osseuses. Des effets anti-tumoraux ont été… (more)

▼

Les métastases osseuses sont une complication majeure des cancers du sein. Les bisphosphonates (BPs) bloquent la progression des lyses osseuses. Des effets anti-tumoraux ont été mis en évidence mais à des doses importantes incompatibles avec un usage clinique. La forte affinité des BPs pour le minéral osseux limite leur biodisponibilité et amoindrit donc leur potentiel antitumoral in vivo. Mon travail de thèse s'est inscrit dans le cadre de la potentialisation des effets anti-tumoraux des BPs. Les BPs ont été combinés avec des ultrasons de faible intensité (LIUS) dont le rôle est d'induire une stimulation mécanique et une augmentation modérée de la température du milieu insonifié sans effet de cavitation. Les LIUS favorisent la pénétration des BPs dans des cellules tumorales en augmentant le phénomène d'endocytose. In vivo, un traitement répété aux LIUS associé à une dose clinique de BPs entraine une diminution des lyses osseuses ainsi que de la masse tumorale. L'accumulation d'un marqueur, retrouvé dans les moelles des souris traitées aux LIUS, suggère que la pénétration des BPs a été favorisée sous l'effet des LIUS. L'effet de l'association BPs avec les LIUS a ensuite été évalué sur un modèle de tumeur sous-cutanée mammaire. Un ralentissement de la croissance tumorale lors des premiers jours de traitements a été mis en évidence. Une étude menée avec de la doxorubicine et des BPs a permis d'élargir le champ d'application des LIUS pour le traitement du cancer du sein. En conclusion, ces travaux montrent que les LIUS apparaissent comme une solution d'intérêt pour augmenter la pénétration de drogues dans des tumeurs osseuses et mammaires et augmenter leur potentiel antitumoral

Bone metastases are common complications of advanced breast cancer. They increase morbidity of patients and alter their quality of life. Bisphosphonates (BPs) stop the progression of osteolysis. However, BPs do not affect the tumor burden located inside the bone marrow cavity. Antitumoral effects have been shown but with high doses incompatibles with a clinical use. BPs bind also avidly to bone mineral which limits their bioavailability and reduce their antitumoral potential in vivo. This work is incorporated within the framework of the enhancement of antitumoral effects of BPs. BPs were combined with low intensity ultrasound (LIUS), which are known to induce a mechanical stimulation and a slight increase of temperature without involving cavitationnal effect. Initially, LIUS were found to increase the penetration of BPs inside several mammary tumor cell lines without affecting their viability by increasing endocytosis. In vivo, a daily repeated treatment of LIUS associated with a single and clinical dose of BPs lead to a decrease in osteolysis as well as tumor burden. The accumulation of unprenylated Rap1A form was found in bone marrow of mice suggesting that LIUS promote BPs penetration inside cells of the bone cavity. The effect of BPs and LIUS was evaluated in a subcutaneous mammary tumor xenograft. Tumor growth was slowed during the first…

Advisors/Committee Members: Melodelima, David (thesis director), Clezardin, Philippe (thesis director).

Subjects/Keywords: Bisphosphonates; Ultrasons; Métastases osseuses; Cancer du sein; Endocytose; Bisphosphonates; Ultrasound; Bone metastases; Breast cancer; Endocytosis; 616.99

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Tardoski, S. (2015). Traitement des métastases osseuses par association d’un bisphosphonate avec des ultrasons de faible intensité : Treatment of bone metastases with a bisphosphonate and low intensity ultrasound. (Doctoral Dissertation). Université Claude Bernard – Lyon I. Retrieved from http://www.theses.fr/2015LYO10162

Chicago Manual of Style (16^th Edition):

Tardoski, Sophie. “Traitement des métastases osseuses par association d’un bisphosphonate avec des ultrasons de faible intensité : Treatment of bone metastases with a bisphosphonate and low intensity ultrasound.” 2015. Doctoral Dissertation, Université Claude Bernard – Lyon I. Accessed March 08, 2021. http://www.theses.fr/2015LYO10162.

MLA Handbook (7^th Edition):

Tardoski, Sophie. “Traitement des métastases osseuses par association d’un bisphosphonate avec des ultrasons de faible intensité : Treatment of bone metastases with a bisphosphonate and low intensity ultrasound.” 2015. Web. 08 Mar 2021.

Vancouver:

Tardoski S. Traitement des métastases osseuses par association d’un bisphosphonate avec des ultrasons de faible intensité : Treatment of bone metastases with a bisphosphonate and low intensity ultrasound. [Internet] [Doctoral dissertation]. Université Claude Bernard – Lyon I; 2015. [cited 2021 Mar 08]. Available from: http://www.theses.fr/2015LYO10162.

Council of Science Editors:

Tardoski S. Traitement des métastases osseuses par association d’un bisphosphonate avec des ultrasons de faible intensité : Treatment of bone metastases with a bisphosphonate and low intensity ultrasound. [Doctoral Dissertation]. Université Claude Bernard – Lyon I; 2015. Available from: http://www.theses.fr/2015LYO10162

29. Eckel, Bénédicte. Etude du rôle des récepteurs de guidage axonal Robo1 et Robo4 dans la formation et le développement des métastases osseuses : Study of the role of axon guidance receptors Robo1 and Robo4 in the formation and development of bone metastases.

Degree: Docteur es, Sciences de la vie, 2012, Université Claude Bernard – Lyon I

URL: http://www.theses.fr/2012LYO10311

►

Les métastases osseuses sont des complications fréquentes de nombreuses tumeurs solides et sontresponsables, sur le plan clinique, de fractures osseuses, d’hypercalcémie et de douleurs. A… (more)

▼

Les métastases osseuses sont des complications fréquentes de nombreuses tumeurs solides et sontresponsables, sur le plan clinique, de fractures osseuses, d’hypercalcémie et de douleurs. A l’heure actuelle,il n’existe aucun traitement curatif ; la compréhension des mécanismes impliqués dans la formation et ledéveloppement des métastases osseuses est donc nécessaire afin d’envisager de nouvelles approchesthérapeutiques.Une analyse transcriptomique comparative entre une lignée humaine de cancer du sein, les MDA-MB-231, et leur sous-population ostéotropique, les B02, a montré une surexpression de composants de la voie designalisation Slit/Robo.Les récepteurs Robo et leurs ligands Slits, initialement identifiés comme facteurs clés du guidage axonal lorsdu développement, sont également impliqués dans la migration des cellules cancéreuses.Afin d’étudier le rôle de ces récepteurs Robo1 et 4 dans la dissémination métastatique à l’os, nousavons inhibé l’expression de ces gènes dans les cellules B02. Des expériences in vitro et in vivo montrentalors un rôle antagoniste de Robo1/4. En effet, l’inhibition de Robo1 augmente la croissance des tumeursprimaires, tandis que celle de Robo4 la diminue. Ces récepteurs régulent également différemment laformation de lésions ostéolytiques ainsi que la croissance tumorale de ces métastases. In vitro, l’absence deRobo1 augmente l’invasion, tandis que celle de Robo4 la diminue. Nous avons également montré quel’inhibition de Robo4 ralentit la colonisation de la moelle osseuse par les cellules B02 à des temps précoces.Enfin, l’étude d’une cohorte de patientes atteintes d’un cancer du sein montre une corrélation entrel’expression de Robo4 et la rechute métastatique osseuse.Cette étude montre l’implication de la voie Slit/Robo dans la dissémination métastatique à l’os, etsemble par conséquent constituer une approche thérapeutique judicieuse pour traiter ces métastases.

Bone metastases are a common complication of many solid tumors and are clinically responsible ofbone fractures, hypercalcemia, and pain. Currently, there is no curative treatment; understanding themechanisms involved in the formation and development of bone metastases is therefore necessary toconsider new therapeutic approaches.A comparative transcriptomic analysis between the human breast cancer cell line MDA-MB-231, andits osteotropic subpopulation, B02, has shown an up-regulation of Slit/Robo signaling pathway.Robo receptors and their ligands Slits were initially identified as key factors in axon guidance duringdevelopment. However, these proteins are also involved in the migration of cancer cells.To investigate the role of these receptors Robo1 and 4 in breast cancer bone metastasis, theexpression of these genes was inhibited in B02 cells. In vitro and in vivo experiments point out antagonisticrole of Robo1/4. Indeed, inhibition of Robo1 expression increases primary tumors growth, while Robo4invalidation reduces it. These receptors also differently regulate the formation of osteolytic lesions and extentof skeletal tumor…

Advisors/Committee Members: Clezardin, Philippe (thesis director), Diaz, Chantal (thesis director).

Subjects/Keywords: Cancer du sein; Métastases osseuses; Robo1/4; Slit2; Invasion; Breast cancer; Bone metastases; Robo1/4; Slit2; Invasion; 616.99

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Eckel, B. (2012). Etude du rôle des récepteurs de guidage axonal Robo1 et Robo4 dans la formation et le développement des métastases osseuses : Study of the role of axon guidance receptors Robo1 and Robo4 in the formation and development of bone metastases. (Doctoral Dissertation). Université Claude Bernard – Lyon I. Retrieved from http://www.theses.fr/2012LYO10311

Chicago Manual of Style (16^th Edition):

Eckel, Bénédicte. “Etude du rôle des récepteurs de guidage axonal Robo1 et Robo4 dans la formation et le développement des métastases osseuses : Study of the role of axon guidance receptors Robo1 and Robo4 in the formation and development of bone metastases.” 2012. Doctoral Dissertation, Université Claude Bernard – Lyon I. Accessed March 08, 2021. http://www.theses.fr/2012LYO10311.

MLA Handbook (7^th Edition):

Eckel, Bénédicte. “Etude du rôle des récepteurs de guidage axonal Robo1 et Robo4 dans la formation et le développement des métastases osseuses : Study of the role of axon guidance receptors Robo1 and Robo4 in the formation and development of bone metastases.” 2012. Web. 08 Mar 2021.

Vancouver:

Eckel B. Etude du rôle des récepteurs de guidage axonal Robo1 et Robo4 dans la formation et le développement des métastases osseuses : Study of the role of axon guidance receptors Robo1 and Robo4 in the formation and development of bone metastases. [Internet] [Doctoral dissertation]. Université Claude Bernard – Lyon I; 2012. [cited 2021 Mar 08]. Available from: http://www.theses.fr/2012LYO10311.

Council of Science Editors:

Eckel B. Etude du rôle des récepteurs de guidage axonal Robo1 et Robo4 dans la formation et le développement des métastases osseuses : Study of the role of axon guidance receptors Robo1 and Robo4 in the formation and development of bone metastases. [Doctoral Dissertation]. Université Claude Bernard – Lyon I; 2012. Available from: http://www.theses.fr/2012LYO10311

Freie Universität Berlin

30. Janssen, Jan-Carlo. Evaluation der Effektivität der Knochenmetastasen-Detektion mit der 68Ga-PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom.

Degree: 2019, Freie Universität Berlin

URL: http://dx.doi.org/10.17169/refubium-25907

► Purpose: The aim of this study was to compare sensitivity and specificity of 68Ga-PSMA-PET and 99mTc-DPD-SPECT in detecting bone metastases in prostate cancer (PC) patients.… (more)

▼ Purpose: The aim of this study was to compare sensitivity and specificity of 68Ga-PSMA-PET and 99mTc-DPD-SPECT in detecting bone metastases in prostate cancer (PC) patients. Additionally, it was evaluated to what extent each modality profits from a fusion with a low-dose CT scan. Methods: For this retrospective study, 54 PC patients who received 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT within 80 days were included. All patients were independently analysed by two observers focused on bone lesions. The first look analysis was performed on the 68Ga-PSMA-PET and 99mTc-DPD-SPECT images. Up to five lesions in nine body regions (Skull, Clavicle/Scapula, Ribs/Sternum, Cervical Spine, Thoracic Spine, Lumbar Spine, Hip, Upper Extremities, Lower Extremities) were counted. In a second look analysis the SPECT and PET images were fused with the low-dose CT images. Again, every patient was reviewed. Osseous lesions were classified as benign, malignant or equivocal. Regarding the statistical analysis, equivocal lesions were regarded as positive in a pessimistic view and as negative in an optimistic view. The reference standard was generated by defining a best valuable comparator (BVC) as a reference database for bone lesions in all patients. Lesion, region and patient based analysis was performed with and without CT fusion. Sensitivities, specificities and accuracies (as “area-under-the-curve”=AUC) were calculated using receiver-operating-characteristics (ROC) analysis. Results: Patient based analysis: In 29 out of 54 Patients bone metastases were validated by BVC. Accuracies measured as AUC for 68Ga-PSMA-PET, 99mTc-SPECT, 68Ga-PSMA-PET/CT and 99mTc-SPECT/CT were 0.97-0.96; 1,00; 0.86-0.83; und 0.83, respectively with ranges representing optimistic vs. pessimistic view. The accuracies were significantly higher in PET and PET/CT than in SPECT and SPECT/CT. Region based analysis: Sensitivities of PET were 91.8-97.7% and specificities were 100-99.5%. The merged PET/CT had a sensitivity of 97.7% and a specificity of 100%. The SPECT had a sensitivity of 61.2-70.6% and a specificity of 99.8-98.3%. The merged SPECT/CT had a sensitivity of 69.4% and a specificity of 98.3%. Sensitivity and specificity were significant higher in PET and PET/CT than in SPECT and SPECT/CT. The amount of correct classifications of equivocal lesions by CT was significantly higher in PET (100%) compared to SPECT (52.4%). Conclusion: 68Ga-PSMA-PET performs better than 99mTc-DPD-SPECT in detecting bone metastases in PC patients. Additionally, 68Ga-PSMA-PET benefits more from a fusion with a low-dose CT than 99mTc-DPD-SPECT. Advisors/Committee Members: male (gender), N.N. (firstReferee), N.N. (furtherReferee).

Subjects/Keywords: prostate cancer; psma; pet; ct; bone metastases; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Janssen, J. (2019). Evaluation der Effektivität der Knochenmetastasen-Detektion mit der 68Ga-PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-25907

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Janssen, Jan-Carlo. “Evaluation der Effektivität der Knochenmetastasen-Detektion mit der 68Ga-PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom.” 2019. Thesis, Freie Universität Berlin. Accessed March 08, 2021. http://dx.doi.org/10.17169/refubium-25907.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Janssen, Jan-Carlo. “Evaluation der Effektivität der Knochenmetastasen-Detektion mit der 68Ga-PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom.” 2019. Web. 08 Mar 2021.

Vancouver:

Janssen J. Evaluation der Effektivität der Knochenmetastasen-Detektion mit der 68Ga-PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom. [Internet] [Thesis]. Freie Universität Berlin; 2019. [cited 2021 Mar 08]. Available from: http://dx.doi.org/10.17169/refubium-25907.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Janssen J. Evaluation der Effektivität der Knochenmetastasen-Detektion mit der 68Ga-PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom. [Thesis]. Freie Universität Berlin; 2019. Available from: http://dx.doi.org/10.17169/refubium-25907

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations